Antitrem2 antibodies and uses thereof

By developing the anti-TREM2 antibody "Ab-1", the problem of difficulty in treating leukoencephalopathy with axonal globulin and pigmentogenic glial cells in the prior art has been solved, and effective treatment of ALSP has been achieved, significantly slowing down disease progression and promoting Neural tissue repair.

CN118900846APending Publication Date: 2024-11-05VIGIL NEUOSCIENCE INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280089650.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-01
Filing Date
2022-11-22
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat leukoencephalopathy with axonal sphere and glial cells pigmentosa (ALSP) in human patients, and there is a lack of effective treatment methods for TREM2 receptors.

Method used

An anti-TREM2 antibody preparation, called "Ab-1", was developed, which regulates the activity of microglia, slows disease progression and promotes neural tissue repair by activating TREM2 receptors, and is used to treat ALSP.

Benefits of technology

Anti-TREM2 antibody "Ab-1" significantly slowed down the disease progression of ALSP, enhanced neural tissue repair mechanisms, and showed good tolerance and safety in non-human primates, providing a potential treatment plan.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004955141060000041
    Figure BDA0004955141060000041
  • Figure BDA0004955141060000051
    Figure BDA0004955141060000051
  • Figure BDA0004955141060000091
    Figure BDA0004955141060000091
Patent Text Reader

Abstract

The present invention provides anti-TREM2 antibodies, formulations thereof, and methods of their use.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims the benefit of U.S. Provisional Application No. 63 / 381,897 filed on November 1, 2022, U.S. Provisional Application No. 63 / 264,428 filed on November 22, 2021, and Greek Application No. 20210100820 filed on November 22, 2021, the contents of which are incorporated herein by reference in their entirety.

[0003] Sequence Listing

[0004] The contents of the electronically submitted Sequence Listing XML (Name: 403433-013WO_SL; Size: 331,607 bytes; Creation Date: November 18, 2022) are incorporated herein by reference in their entirety. Technical Field

[0005] The present invention provides an anti-TREM2 antibody, formulations thereof, and methods of using the same to treat adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in human patients. Background Art

[0006] Triggering receptor 2 expressed on myeloid cells (TREM2) is a receptor in the central nervous system whose expression is limited to microglia, and its mutation increases the risk of neurodegenerative diseases such as Alzheimer's disease and frontotemporal dementia (Ulland and Colonna, Nature Reviews, 14, 2018). TREM2 receptors affect microglial state and function through their interactions with various ligands, and such ligands are essential for sensing tissue damage and minimizing the onset of neuropathies (Deczkowsk, Cell, 181, 2020). In addition, TREM2 receptor agonism is required for microglia to progress to a neuroprotective disease-associated (DAM) phenotype (Keren-Shaul Cell, 169, 2017). Summary of the invention

[0007] Disclosed herein are compositions of triggering receptor 2 (TREM2) antibodies expressed on myeloid cells, and methods of using them. The response of microglia to changes in the CNS environment is activated by TREM2 and its associated protein kinase complex DAP12. TREM2 / DAP12 signals act as a major regulator, converting microglia from a steady state to a neurological disease-related state, and producing anti-inflammatory responses and neurotrophic factors to protect damaged neurons and achieve neural tissue regeneration. In one embodiment, the anti-TREM2 antibody is "Ab-1", i.e., a monoclonal antibody capable of binding to TREM2, also referred to herein as VGL101. Anti-TREM2 antibody "Ab-1" can be used to regulate the activity of such cells, but does not inhibit or damage the immune system. Without wishing to be bound by any particular theory, anti-TREM2 antibody "Ab-1" activates TREM2, slows disease progression, and enhances the neural tissue repair mechanism regulated by microglia.

[0008] Therefore, in one aspect, the present invention provides a liquid formulation of an anti-TREM2 antibody. In one embodiment, the anti-TREM2 antibody is "Ab-1", and the liquid formulation further comprises a pharmaceutically acceptable excipient and / or carrier. In some embodiments, the liquid formulation of the present invention comprises sodium acetate. In some embodiments, the liquid formulation of the present invention comprises sucrose. In some embodiments, the liquid formulation of the present invention comprises polysorbate 80.

[0009] In another aspect, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering a therapeutically effective amount of an anti-TREM2 antibody to a patient in need thereof. In some embodiments, the anti-TREM2 antibody is an anti-TREM2 antibody "Ab-1". In some embodiments, the method of the present invention comprises administering a liquid formulation to a patient in need thereof, the liquid formulation comprising an anti-TREM2 antibody "Ab-1", as described herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] Figure 1 Is a graph showing mean serum concentrations (in μg / mL) of anti-TREM2 antibody "Ab-1" over time in healthy volunteers (receiving a single intravenous infusion of 1 mg / kg, 3 mg / kg, 10 mg / kg, 20 mg / kg, or 30 mg / kg). N=6 for each cohort except 10 mg / kg, N=5. Data for the 30 mg / kg dose were only available 28 days after dosing.

[0011] Figure 2is a graph showing the mean serum concentration (in μg / mL) of the anti-TREM2 antibody "Ab-1" over time in healthy volunteers (receiving a dose of 20 mg / kg, administered intravenously once every 28 days, for a total of three infusions). N=12

[0012] Figure 3A Graph showing the effect of anti-TREM2 antibody "Ab-1" on sTREM2 in the cerebrospinal fluid (CSF) of 18 healthy volunteers (administered at single intravenous doses of 3 mg / kg, 10 mg / kg, and 20 mg / kg). Data are plotted as the mean change in sTREM2 (in pg / mL) in CSF over 336 hours (14 days) relative to baseline. N=6 per dose. Figure 3B Graph showing the effect of anti-TREM2 antibody "Ab-1" on CSF sTREM2 in 6 healthy volunteers (administered 20 mg / kg intravenously every 28 days for a total of three infusions). Mean CSF levels of sTREM2 were evaluated at baseline (pre-dose), 48 hours and 672 hours (28 days) after the third and final doses. *p<0.05.

[0013] Figure 4A Is a graph showing the effect of anti-TREM2 antibody "Ab-1" on sCSF1R in CSF of 18 healthy volunteers (administered at single intravenous doses of 3 mg / kg, 10 mg / kg, and 20 mg / kg). Data are plotted as the mean change in sCSF1R (in pg / mL) in CSF over 336 hours (14 days) relative to baseline. N=6 per dose. Figure 4B is a graph showing the effect of anti-TREM2 antibody "Ab-1" on CSF sCSF1R in 6 healthy volunteers (administered 20 mg / kg intravenously every 28 days, for a total of three infusions). Mean CSF levels of sCSF1R were evaluated at baseline (pre-dose), 48 hours and 672 hours (28 days) after the third dose and the final dose. *p<0.05. DETAILED DESCRIPTION

[0014] 1. General Description of Certain Embodiments of the Invention

[0015] Described herein are formulations of anti-TREM2 antibodies (such as "Ab-1") suitable for administration to a subject (e.g., a human subject). It has been found that in an in vitro cytokine release assay, at concentrations up to 10 μg / mL, the anti-TREM2 antibody "Ab-1" had no effect on the release of granulocyte colony stimulating factor (CSF), monocyte chemoattractant protein-1 (MCP-1), 10 kDa interferon-γ induced protein (IP-10), interleukin (IL) -1β, IL-2, IL-4, IL-6, IL-10, IL-12p40, IL-13, and IFN-γ. Minimal but dose-related increases in tumor necrosis factor-α release were observed at the two highest concentrations (4 μg / mL and 10 μg / mL). However, this increase is within the range reported for other commercially available monoclonal antibodies, and no increase in TNF-α in vivo was observed at any dose tested in the GLP non-human primate (NHP) study.

[0016] The anti-TREM2 antibody "Ab-1" was well tolerated in NHPs after repeated doses up to 200 mg / kg were administered intravenously weekly for 1 month. No test article-related effects on clinical signs, body weight, food consumption, ophthalmic examinations, or clinical pathology parameters (serum chemistry, hematology, coagulation, and urinalysis) were observed. Macroscopic and microscopic examinations did not reveal any adverse findings or effects on organ weights. Safety pharmacology parameters were included in the GLP toxicology study of NHPs in accordance with the International Council for Harmonization (ICH) Good Clinical Practice (GCP) Tripartite Guideline S6 (ICH S6). No CNS effects were observed in detailed neurobehavioral examinations, and the electrocardiogram (ECG) showed no findings related to the anti-TREM2 antibody "Ab-1".

[0017] The no observed adverse effect level (NOAEL) was considered to be 200 mg / kg. The following exposures were observed after the fourth 200 mg / kg once every 7 days (q7d) dose:

[0018] On Day 22, for 200 mg / kg, the serum area under the curve from pre-dose (time 0) to the time of quantifiable concentration at 168 hours (AUC0-168hr): 838000 h*μg / mL

[0019] On day 22, for 200 mg / kg, maximum serum / cerebrospinal fluid concentration (Cmax): 8320 μg / mL

[0020] In cynomolgus monkeys, the dose was administered q7d for 29 days. As part of the MAD portion of the study, the intended dosing regimen for administration to humans is once every 28 days. To calculate the NOAEL limit, the AUC0-168hr on day 22 was multiplied by 4 (the number of doses received by the cynomolgus monkey in a 28-day period) based on q7d dosing in cynomolgus monkeys; the Cmax NOAEL limit remained unchanged:

[0021] NOAEL limit for the area under the serum or CSF concentration-time curve from pre-dose (time 0) to infinite time (AUClast + Clast / λz) (AUC0-∞): 838,000h*μg / mL×4=3,350,000h*μg / mL

[0022] NOAEL limit for Cmax: 8,320 μg / mL

[0023] The NHP NOAEL of 200 mg / kg provides a safety margin above the expected Cmax and AUC in healthy volunteers at a starting dose of 1 mg / kg. INF 344 and 337 times higher.

[0024] Therefore, in one aspect, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1", and a pharmaceutically acceptable excipient and / or carrier. In some embodiments, the pharmaceutically acceptable excipient and / or carrier of the present invention is selected from those described herein.

[0025] In another aspect, the invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering a therapeutically effective amount of an anti-TREM2 antibody to a patient in need thereof. In some embodiments, the method of the invention comprises administering a therapeutically effective amount of a liquid formulation as described herein to a patient in need thereof.

[0026] In some embodiments, an anti-TREM2 antibody comprises a light chain variable region comprising CDRL1 having an amino acid sequence according to SEQ ID NO:2; CDRL2 having an amino acid sequence according to SEQ ID NO:3; and CDRL3 having an amino acid sequence according to SEQ ID NO:4, and a heavy chain variable region comprising CDRH1 having an amino acid sequence according to SEQ ID NO:6; CDRH2 having an amino acid sequence according to SEQ ID NO:7; and CDRH3 having an amino acid sequence according to SEQ ID NO:8.

[0027] In some embodiments, the anti-TREM2 antibody comprises a light chain variable region having an amino acid sequence according to SEQ ID NO:1 and a heavy chain variable region having an amino acid sequence according to SEQ ID NO:5.

[0028] In some embodiments, the anti-TREM2 antibody is IgG, optionally IgG1.

[0029] In some embodiments, the anti-TREM2 antibody comprises a kappa light chain constant region.

[0030] In some embodiments, the anti-TREM2 antibody is an IgG1 comprising a variant constant region having one or more mutations selected from: R292C, N297G, V302C, D356E, or L358M, according to EU numbering.

[0031] In some embodiments, the anti-TREM2 antibody is the anti-TREM2 antibody "Ab-1."

[0032] 2. definition

[0033] As used herein, the term "anti-TREM2 antibody Ab-1" refers to an anti-TREM2 antibody "Ab-1" comprising a light chain having an amino acid sequence of SEQ ID NO: 9, and a heavy chain having an amino acid sequence of SEQ ID NO: 10. "Ab-1" is used interchangeably with VGL101 and describes an antibody having CAS number 2733621-19-5, which has an amino acid sequence summarized in Table 1 below.

[0034] Table 1: List of amino acid sequences.

[0035]

[0036]

[0037] In some embodiments, the anti-TREM2 antibody is an anti-TREM2 antibody described in one or more of the following patents: WO 2018 / 195506; U.S. Patent 8,231,878; U.S. Patent Publication 2019 / 0010230; WO 2017 / 062672; WO 2019 / 028292; WO 2018 / 015573; WO 2019 / 055841; WO 2019 / 118513; WO 2020 / 055975; WO2020 / 079580; KR Patent Publication KR20200048069; each of these patents is incorporated herein by reference in its entirety. In some embodiments, the anti-TREM2 antibody is AL002. In some embodiments, the anti-TREM2 antibody is DNL919. In some embodiments, the anti-TREM2 antibody is not “Ab-1” (i.e., VGL101).

[0038] As used herein, the term "pharmaceutically acceptable salt" refers to salts that are suitable for contact with human and lower animal tissues within the scope of reasonable medical judgment without excessive toxicity, irritation, allergic reactions, etc., and that match a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, which is incorporated herein by reference. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable, non-toxic acid addition salts are salts formed by amino groups with inorganic acids or with organic acids, or by using other methods used in the art (such as ion exchange), such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate and the like.

[0039] Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1–4 Representative alkali metal salts or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, etc. Where appropriate, additional pharmaceutically acceptable salts include non-toxic ammonium salts, quaternary ammonium salts and amine cation salts formed using counterions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates.

[0040] Unless otherwise stated, structures depicted herein are also meant to include all isomeric (e.g., enantiomers, diastereomers, and geometric (or conformational) isomers) structural forms; for example, R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the compounds of the present invention are within the scope of the present invention. Unless otherwise stated, all tautomeric forms of the compounds of the present invention are within the scope of the present invention. In addition, unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms. For example, a compound having a structure of the present invention includes substitution of hydrogen with deuterium or tritium, or substitution of hydrogen with isotopically enriched atoms. 13 C or 14 Carbon substitutions at C-rich carbons are within the scope of the invention. Such compounds are useful, for example, as analytical tools, probes in biological assays, or therapeutic agents according to the invention.

[0041] As used herein, "about" or "approximately" means within 20% of a given value or range. In some embodiments, the term "about" refers to within 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of a given value.

[0042] The present invention relates to antibodies that specifically bind to TREM2 (especially human TREM2). In humans, the TREM2 gene is located in the TREM gene cluster at chromosome 6p21.1. The TREM gene cluster encodes four TREM proteins (TREM1, TREM2, TREM4 and TREM5) and two TREM-like proteins (TLT-1 and TLT-2). The TREM2 gene encodes a protein of 230 amino acids, which consists of an extracellular domain, a transmembrane region and a short cytoplasmic tail (Paradowska-Gorycka et al., Human Immunology, Vol. 74: 730-737, 2013). The extracellular domain contains a single V-type Ig-superfamily domain with three potential N-glycosylation sites. The wild-type human TREM2 amino acid sequence (NCBI reference sequence: NP_061838.1) is provided as follows in SEQ ID NO: 354.

[0043] MEPLRLLILLFVTELSGAHNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRWSTHNLWLLSFLRRWNGSTAITDDTLGGTLTITLRNLQPHDAGLYQCQSLHGSE ADTLRKVLVEVLADPLDHRDAGDLWFPGESESFEDAHVEHSISRSLLEGEIPFPPTSILLLLACIFLIKILAASALWAAAWHGQKPGTHPPSELDCGHDPGYQLQTLPGLRDT(SEQ ID NO:354)

[0044] Amino acids 1 to 18 of the wild-type human TREM2 protein (SEQ ID NO: 354) are signal peptides, which are typically removed from the mature protein. The mature human TREM2 protein comprises an extracellular domain at amino acids 19-174 of SEQ ID NO: 354, a transmembrane domain at amino acids 175-195 of SEQ ID NO: 354, and a cytoplasmic domain at amino acids 196-230 of SEQ ID NO: 354. The amino acid sequence of the extracellular domain of human TREM2 (including the signal peptide) is provided below in SEQ ID NO: 355.

[0045] MEPLRLLILLFVTELSGAHNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRWSTHNLWLLSFLRRWNGSTAITDDTLGGTL TITLRNLQPHDAGLYQCQSLHGSEADTLRKVLVEVLADPLDHRDAGDLWFPGESESFEDAHVEHSISRSLLEGEIPFPPTS(SEQ ID NO:355)

[0046] The term "triggering receptor expressed on human myeloid cells-2" or "human TREM2" may refer to a polypeptide of SEQ ID NO: 354, a polypeptide of SEQ ID NO: 355, a polypeptide of SEQ ID NO: 354 or SEQ ID NO: 355 minus the signal peptide (amino acids 1-18), an allelic variant of human TREM2, or a splice variant of human TREM2. In some embodiments, the term "human TREM2" includes naturally occurring variants of TREM2, such as mutations R47H, Q33X (X is a stop codon), Y38C, T66M, D87N, H157Y, R98W, and S116C.

[0047] 3. Description of Exemplary Embodiments

[0048] Antibody

[0049] In one aspect, the present invention provides a method for treating ALSP in a human patient, the method comprising administering to the patient an effective amount of an antigen binding protein or antibody or antigen binding fragment thereof that increases TREM2 activity. In some embodiments, the antibody is an agonist of TREM2. In some embodiments, the antibody is a TREM2 agonist that specifically binds to and activates human TREM2. In some embodiments, the antibody is the anti-human TREM2 antibody VGL101.

[0050] TREM2 agonist antibodies specifically bind to human TREM2 (SEQ ID NO: 354) or the extracellular domain (ECD) of human TREM2 (e.g., the ECD set forth in SEQ ID NO: 355), such as the equilibrium dissociation constant (K D ) is less than 50 nM, less than 25 nM, less than 10 nM, or less than 5 nM. In some embodiments, the TREM2 agonist antibody does not cross-react with other TREM proteins, such as human TREM1. In some embodiments, the TREM2 agonist antibody does not bind to human TREM1.

[0051] In some embodiments, the TREM2 antibody specifically binds to human TREM2 residues 19-174 (SEQ ID NO: 354). In some embodiments, the TREM2 antibody specifically binds to the IgV region of human TREM2, e.g., human TREM2 residues 19-140 (SEQ ID NO: 354).

[0052] In certain embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 29-112 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 29-112 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 29-41 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 29-41 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 47-69 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 47-69 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 76-86 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 76-86 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 91-100 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 91-100 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 99-115 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 99-115 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 104-112 of human TREM2 (SEQ ID NO: 354), or within amino acid residues on the TREM2 protein corresponding to amino acid residues 104-112 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 114-118 of human TREM2 (SEQ ID NO: 354), or within amino acid residues on the TREM2 protein corresponding to amino acid residues 114-118 of SEQ ID NO: 354.In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 130-171 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 130-171 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 139-153 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 139-153 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 139-146 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 139-146 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 130-144 of human TREM2 (SEQ ID NO: 354), or within amino acid residues on the TREM2 protein corresponding to amino acid residues 130-144 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 158-171 of human TREM2 (SEQ ID NO: 354), or within amino acid residues on the TREM2 protein corresponding to amino acid residues 158-171 of SEQ ID NO: 354.

[0053] In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 43-50 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 43-50 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 49-57 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 49-57 of SEQ ID NO: 354. In some embodiments, the anti-TREM2 antibodies of the present disclosure bind to one or more amino acids within amino acid residues 139-146 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on the TREM2 protein corresponding to amino acid residues 139-146 of SEQ ID NO: 354. In some embodiments, an anti-TREM2 antibody of the present disclosure binds to one or more amino acids within amino acid residues 140-153 of human TREM2 (SEQ ID NO: 354) or within amino acid residues on a TREM2 protein corresponding to amino acid residues 140-153 of SEQ ID NO: 354. In some embodiments, the TREM2 antibody specifically binds to the stem region of human TREM2, e.g., amino acid residues 145-174 of human TREM2.

[0054] In some embodiments, the antibody or antigen-binding fragment thereof specifically binds TREM2 and prevents degradation or cleavage of TREM2.

[0055] In some embodiments, the antibody is a polyclonal antibody. In some embodiments, the antibody is a monoclonal antibody. In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a humanized antibody. In some embodiments, the antibody is a human antibody, particularly a fully human antibody. In some embodiments, the antibody is a bispecific or other multivalent antibody. In some embodiments, the antibody is a single-chain antibody.

[0056] In some embodiments, a TREM2 activating antibody comprises a light chain variable region comprising the complementarity determining regions CDRL1, CDRL2, and CDRL3 described herein and a heavy chain variable region comprising the complementarity determining regions CDRH1, CDRH2, and CDRH3.

[0057] In certain embodiments, a TREM2 agonist antigen binding protein of the present invention comprises at least one light chain variable region comprising CDRL1, CDRL2, and CDRL3 from an anti-TREM2 agonist antibody described herein, and at least one heavy chain variable region comprising CDRH1, CDRH2, and CDRH3.

[0058] In some embodiments, the TREM2 activating antibody comprises a light chain variable region and a heavy chain variable region as described herein. The light chain and heavy chain variable regions or CDRs can be from any anti-TREM2 antibody described herein or a variant thereof.

[0059] A. PCT patent application publication number WO2018 / 195506A1

[0060] In some embodiments, the TREM2 agonist is an antigen binding protein or antibody or antigen binding fragment thereof as described in PCT Patent Application Publication No. WO2018 / 195506A1 (which is incorporated herein by reference in its entirety).

[0061] In some embodiments, the TREM2 agonist antigen binding protein includes CDRL1 or a variant thereof having one, two, three, or four amino acid substitutions; CDRL2 or a variant thereof having one, two, three, or four amino acid substitutions; CDRL3 or a variant thereof having one, two, three, or four amino acid substitutions; CDRH1 or a variant thereof having one, two, three, or four amino acid substitutions; CDRH2 or a variant thereof having one, two, three, or four amino acid substitutions; and CDRH3 or a variant thereof having one, two, three, or four amino acid substitutions, wherein the amino acid sequences of CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3 and exemplary light chains and variable regions are provided in Tables 1A and 1B below.

[0062] Table 1A: Exemplary anti-human TREM2 antibody light chain variable region amino acid sequences

[0063]

[0064]

[0065]

[0066]

[0067] Table 1B. Exemplary anti-human TREM2 antibody heavy chain variable region amino acid sequences

[0068]

[0069]

[0070]

[0071] As described above, the TREM2 agonist antigen binding protein may comprise one or more of the CDRs present in Table 1 (VGL101), Table 1A (light chain CDRs; i.e., CDRL), and Table 1B (heavy chain CDRs, i.e., CDRH).

[0072] In some embodiments, the TREM2 agonist antigen binding protein comprises one or more light chain CDRs selected from (i) a CDRL1 selected from SEQ ID NOs: 11 to 18 or 356 to 361, (ii) a CDRL2 selected from SEQ ID NOs: 19 to 30, and (iii) a CDRL3 selected from SEQ ID NOs: 31 to 45, and (iv) a CDRL of (i), (ii) and (iii) containing one or more (e.g., one, two, three, four or more) amino acid substitutions (e.g., conservative amino acid substitutions), deletions or insertions of no more than five, four, three, two or one amino acids. In these and other embodiments, the TREM2 agonist antigen binding protein comprises one or more heavy chain CDRs selected from (i) a CDRH1 selected from SEQ ID NOs: 77 to 86, (ii) a CDRH2 selected from SEQ ID NOs: 87 to 94, and (iii) a CDRH3 selected from SEQ ID NOs: 95 to 109, and (iv) a CDRH of (i), (ii) and (iii) containing one or more (e.g., one, two, three, four or more) amino acid substitutions (e.g., conservative amino acid substitutions), deletions or insertions of no more than five, four, three, two or one amino acids.

[0073] In some embodiments, the TREM2 agonist antigen binding protein may comprise 1, 2, 3, 4, 5, or 6 variant forms of the CDRs listed in Tables 1A and 1B, each having at least 80%, 85%, 90%, or 95% sequence identity with the CDR sequences listed in Tables 1A and 1B. In some embodiments, the TREM2 agonist antigen binding protein comprises 1, 2, 3, 4, 5, or 6 CDRs listed in Tables 1A and 1B, each CDR differing from the CDRs listed in these tables by no more than 1, 2, 3, 4, or 5 amino acids.

[0074] In some embodiments, the TREM2 agonist antigen binding protein comprises a CDRL1 comprising a sequence selected from SEQ ID NOs: 11-18 or 356-361, or variants thereof having one, two, three, or four amino acid substitutions; a CDRL2 comprising a sequence selected from SEQ ID NOs: 19-30, or variants thereof having one, two, three, or four amino acid substitutions; a CDRL3 comprising a sequence selected from SEQ ID NOs: 31-45, or variants thereof having one, two, three, or four amino acid substitutions; a CDRH1 comprising a sequence selected from SEQ ID NOs: 77-86, or variants thereof having one, two, three, or four amino acid substitutions; a CDRH2 comprising a sequence selected from SEQ ID NOs: 87-94, or variants thereof having one, two, three, or four amino acid substitutions; and a CDRH3 comprising a sequence selected from SEQ ID NOs: 95-109, or variants thereof having one, two, three, or four amino acid substitutions.

[0075] In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises CDRL1, wherein the CDRL1 contains a sequence selected from SEQ ID NO: 11-18 or 356-361; CDRL2, wherein the CDRL2 contains a sequence selected from SEQ ID NO: 19-30; CDRL3, wherein the CDRL3 contains a sequence selected from SEQ ID NO: 31-45; CDRH1, wherein the CDRH1 contains a sequence selected from SEQ ID NO: 77-86; CDRH2, wherein the CDRH2 contains a sequence selected from SEQ ID NO: 87-94; and CDRH3, wherein the CDRH3 contains a sequence selected from SEQ ID NO: 95-109.

[0076] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein:

[0077] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 356, 19 and 31, respectively;

[0078] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 20 and 32, respectively;

[0079] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 21 and 33, respectively;

[0080] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 20 and 33, respectively;

[0081] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 358, 22 and 34, respectively;

[0082] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 359, 22 and 35, respectively;

[0083] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 360, 22 and 36, respectively;

[0084] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 37, respectively;

[0085] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 11, 23 and 38, respectively;

[0086] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 12, 24 and 39, respectively;

[0087] (k) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 13, 25 and 40, respectively;

[0088] (1) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 14, 26 and 41, respectively;

[0089] (m) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 15, 27 and 42, respectively;

[0090] (n) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 43, respectively;

[0091] (o) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 29 and 44, respectively; or

[0092] (p) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 18, 30 and 45, respectively.

[0093] In some embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0094] (a) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 87 and 95, respectively;

[0095] (b) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 78, 88 and 96, respectively;

[0096] (c) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 78, 88 and 97, respectively;

[0097] (d) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 78, 89 and 96, respectively;

[0098] (e) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 90 and 98, respectively;

[0099] (f) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 79, 90 and 99, respectively;

[0100] (g) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 80, 91 and 100, respectively;

[0101] (h) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 91 and 101, respectively;

[0102] (i) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 82, 92 and 102, respectively;

[0103] (j) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 91 and 103, respectively;

[0104] (k) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 91 and 104, respectively;

[0105] (1) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 83, 93 and 105, respectively;

[0106] (m) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 84, 91 and 106, respectively;

[0107] (n) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0108] (o) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 86, 94 and 108, respectively; or

[0109] (p) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 109, respectively.

[0110] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0111] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 356, 19 and 31, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 87 and 95, respectively;

[0112] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 20 and 32, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 78, 88 and 96, respectively;

[0113] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 21 and 33, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 78, 88 and 97, respectively;

[0114] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 20 and 33, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 78, 88 and 97, respectively;

[0115] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 20 and 33, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 78, 89 and 96, respectively;

[0116] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 358, 22 and 34, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 87 and 95, respectively;

[0117] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 359, 22 and 35, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 90 and 98, respectively;

[0118] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 360, 22 and 36, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 79, 90 and 99, respectively;

[0119] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 37, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 80, 91 and 100, respectively;

[0120] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 37, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 91 and 101, respectively;

[0121] (k) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 11, 23 and 38, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 82, 92 and 102, respectively;

[0122] (1) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 12, 24 and 39, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 91 and 103, respectively;

[0123] (m) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 13, 25 and 40, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 91 and 104, respectively;

[0124] (n) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 14, 26 and 41, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 83, 93 and 105, respectively;

[0125] (o) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 15, 27 and 42, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 84, 91 and 106, respectively;

[0126] (p) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0127] (q) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 29 and 44, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 86, 94 and 108, respectively; or

[0128] (r) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 18, 30 and 45, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 109, respectively.

[0129] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDRL1, CDRL2 and CDRL3, the heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 37, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 80, 91 and 100, respectively. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDRL1, CDRL2 and CDRL3, the heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 37, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 91 and 101, respectively. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein CDRL1, CDRL2, and CDRL3 have the sequences of SEQ ID NOs: 15, 27, and 42, respectively, and CDRH1, CDRH2, and CDRH3 have the sequences of SEQ ID NOs: 84, 91, and 106, respectively. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein CDRL1, CDRL2, and CDRL3 have the sequences of SEQ ID NOs: 16, 28, and 43, respectively, and CDRH1, CDRH2, and CDRH3 have the sequences of SEQ ID NOs: 85, 91, and 107, respectively. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDRL1, CDRL2 and CDRL3, the heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 29 and 44, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 86, 94 and 108, respectively.In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region comprises CDRL1, CDRL2 and CDRL3, and the heavy chain variable region comprises CDRH1, CDRH2 and CDRH3, wherein CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 359, 22 and 35, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 90 and 98, respectively.

[0130] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence selected from SEQ ID NOs: 46-63 and a heavy chain variable region comprising a sequence selected from SEQ ID NOs: 110-126. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 46 and a heavy chain variable region comprising a sequence of SEQ ID NO: 110. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 47 and a heavy chain variable region comprising a sequence of SEQ ID NO: 111. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 48 and a heavy chain variable region comprising a sequence of SEQ ID NO: 112. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 49 and a heavy chain variable region comprising the sequence of SEQ ID NO: 113. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 50 and a heavy chain variable region comprising the sequence of SEQ ID NO: 114. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 51 and a heavy chain variable region comprising the sequence of SEQ ID NO: 110. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 53 and a heavy chain variable region comprising the sequence of SEQ ID NO: 116. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 54 and a heavy chain variable region comprising the sequence of SEQ ID NO: 117. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 55 and a heavy chain variable region comprising the sequence of SEQ ID NO: 118. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 56 and a heavy chain variable region comprising the sequence of SEQ ID NO: 119. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 57 and a heavy chain variable region comprising the sequence of SEQ ID NO: 120.In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 58 and a heavy chain variable region comprising the sequence of SEQ ID NO: 121. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 59 and a heavy chain variable region comprising the sequence of SEQ ID NO: 122. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 60 and a heavy chain variable region comprising the sequence of SEQ ID NO: 123. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 61 and a heavy chain variable region comprising the sequence of SEQ ID NO: 124. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 62 and a heavy chain variable region comprising the sequence of SEQ ID NO: 125. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 63 and a heavy chain variable region comprising the sequence of SEQ ID NO: 126. In yet another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 52 and a heavy chain variable region comprising the sequence of SEQ ID NO: 115.

[0131] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region selected from LV-01, LV-02, LV-03, LV-04, LV-05, LV-06, LV-07, LV-08, LV-09, LV-10, LV-11, LV-12, LV-13, LV-14, LV-15, LV-16, LV-17, and LV-18 as shown in Table 1A, and / or a heavy chain variable region selected from HV-01, HV-02, HV-03, HV-04, HV-05, HV-06, HV-07, HV-08, HV-09, HV-10, HV-11, HV-12, HV-13, HV-14, HV-15, HV-16 and HV-17 as shown in Table 1B, and functional fragments, derivatives, mutant proteins and variants of these light and heavy chain variable regions.

[0132] In some embodiments, each light chain variable region listed in Table 1A can be combined with any heavy chain variable region listed in Table 1B to form an anti-TREM2 binding domain of an antigen binding protein of the invention. Examples of such combinations include, but are not limited to: LV-01 (SEQ ID NO:46) and HV-01 (SEQ ID NO:110); LV-02 (SEQ ID NO:47) and HV-02 (SEQ ID NO:111); LV-03 (SEQ ID NO:48) and HV-03 (SEQ ID NO:112); LV-04 (SEQ ID NO:49) and HV-04 (SEQ ID NO:113); LV-05 (SEQ ID NO:50) and HV-05 (SEQ ID NO:114); LV-06 (SEQ ID NO:51) and HV-01 (SEQ ID NO:110); LV-07 (SEQ ID NO:52) and HV-06 (SEQ ID NO:115); LV-08 (SEQ ID NO:53) and HV-07 (SEQ ID NO:116); LV-09 (SEQ ID NO:54) and HV-09 (SEQ ID NO:117). NO: 54) and HV-08 (SEQ ID NO: 117); LV-10 (SEQ ID NO: 55) and HV-09 (SEQ ID NO: 118); LV-11 (SEQ ID NO: 56) and HV-10 (SEQ ID NO: 119); LV-12 (SEQ ID NO: 57) and HV-11 (SEQ ID NO: 120); LV-13 (SEQ ID NO: 58) and HV-12 (SEQ ID NO: 121); LV-14 (SEQ ID NO: 59) and HV-13 (SEQ ID NO: 122); LV-15 (SEQ ID NO: 60) and HV-14 (SEQ ID NO: 123); LV-16 (SEQ ID NO: 61) and HV-15 (SEQ ID NO: 124); LV-17 (SEQ ID NO: 62) and HV-16 (SEQ ID NO: 125). NO:125); and LV-18 (SEQ ID NO:63) and HV-17 (SEQ ID NO:126).

[0133] In certain embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region containing the sequence of LV-09 (SEQ ID NO: 54) and a heavy chain variable region containing the sequence of HV-08 (SEQ ID NO: 117). In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region containing the sequence of LV-10 (SEQ ID NO: 55) and a heavy chain variable region containing the sequence of HV-09 (SEQ ID NO: 118). In other embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region containing the sequence of LV-15 (SEQ ID NO: 60) and a heavy chain variable region containing the sequence of HV-14 (SEQ ID NO: 123). In still other embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region containing the sequence of LV-16 (SEQ ID NO: 61) and a heavy chain variable region containing the sequence of HV-15 (SEQ ID NO: 124). In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region comprising the sequence of LV-17 (SEQ ID NO: 62) and a heavy chain variable region comprising the sequence of HV-16 (SEQ ID NO: 125). In certain embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region comprising the sequence of LV-07 (SEQ ID NO: 52) and a heavy chain variable region comprising the sequence of HV-06 (SEQ ID NO: 115).

[0134] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a contiguous amino acid sequence that differs from the sequence of a light chain variable region in Table 1A (i.e., a VL selected from LV-01, LV-02, LV-03, LV-04, LV-05, LV-06, LV-07, LV-08, LV-09, LV-10, LV-11, LV-12, LV-13, LV-14, LV-15, LV-16, LV-17, or LV-18) at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion, or substitution of one amino acid, wherein the deletions, insertions, and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The light chain variable region in some TREM2 agonist antigen binding proteins comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 46-63 (i.e., the light chain variable region in Table 1A). In one embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence at least 90% identical to a sequence selected from SEQ ID NO: 46-63. In another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence at least 95% identical to a sequence selected from SEQ ID NO: 46-63. In yet another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence selected from SEQ ID NO: 46-63. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 54. In other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 55. In yet other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 60. In still other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 61. In certain embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 62. In other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 52.

[0135] In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a contiguous amino acid sequence that differs from the sequence of a heavy chain variable region in Table 1B (i.e., a VH selected from HV-01, HV-02, HV-03, HV-04, HV-05, HV-06, HV-07, HV-08, HV-09, HV-10, HV-11, HV-12, HV-13, HV-14, HV-15, HV-16, or HV-17) at only 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 amino acid residues, wherein each such sequence difference is independently a deletion, insertion, or substitution of one amino acid, wherein the deletions, insertions, and / or substitutions result in no more than 15 amino acid changes relative to the aforementioned variable domain sequence. The heavy chain variable region in some TREM2 agonist antigen binding proteins comprises an amino acid sequence having at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or at least 99% sequence identity with the amino acid sequence of SEQ ID NO: 110-126 (i.e., the heavy chain variable region in Table 1B). In one embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence at least 90% identical to a sequence selected from SEQ ID NO: 110-126. In another embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence at least 95% identical to a sequence selected from SEQ ID NO: 110-126. In yet another embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence selected from SEQ ID NO: 110-126. In some embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 117. In other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 118. In yet other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 123. In still other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 124. In certain embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 125. In other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 115.

[0136] In some embodiments, variants of anti-TREM2 antibodies can be generated by replacing one or more amino acids in the light chain or heavy chain variable region to address chemical liabilities (e.g., aspartate isomerization, asparagine deamidation, tryptophan and methionine oxidation) or correct covariance violations (see, e.g., WO 2012 / 125495, which is hereby incorporated by reference in its entirety). Such variants may have improved biophysical, expression, and / or stability properties compared to the parent antibody. In some embodiments, the TREM2 agonist antigen binding proteins of the present invention comprise a light chain variable region and / or a heavy chain variable region having one or more amino acid substitutions listed in Tables 2A-2F below.

[0137] In some embodiments, additional variants of the anti-TREM2 antibodies described herein can be generated by affinity modulation of any of the anti-TREM2 antibodies described herein. An "affinity modulated antibody" is an antibody comprising one or more amino acid substitutions in its light chain variable region sequence and / or heavy chain variable region sequence that increases or decreases the affinity of the antibody for the target antigen compared to a parent antibody without the amino acid substitutions. Methods for adjusting antibody affinity are known to those skilled in the art and may include CDR walking mutagenesis (Yang et al., J. Mol. Biol., 254, 392-403, 1995), chain shuffling (Marks et al., Bio / Technology, 10, 779-783, 1992), use of E. coli mutant strains (Low et al., J. Mol. Biol., 250, 350-368, 1996), DNA shuffling (Patten et al., Curr. Opin. Biotechnol., 1997, 8: 724-733), phage display (Thompson et al., J. Mol. Biol., 1996, 256: 7-88), PCR technology (Crameri et al., Nature, 1998, 391: 288-291) and other mutagenesis strategies (Barbas et al., Proc Nat. Acad. Sci. USA 91:3809-3813, 1994; Schier et al., Gene 169:147-155, 1995; Yelton et al., J. Immunol. 155:1994-2004, 1995; Jackson et al., J. Immunol. 154(7):3310-9, 1995; and Hawkins et al., J. Mol. Biol., 1992, 226:889-896). Affinity modulation methods are discussed in Hoogenboom, Trends in Biotechnology, 1995, 15:62-70 and Vaughan et al., Nature Biotechnology, 1998, 16535-539. One specific method for generating affinity-modulated variants of the anti-TREM2 antibodies described herein is to use a yeast-displayed Fab mutagenesis library.

[0138] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region that is a variant of the light chain variable region of any anti-TREM2 antibody described herein. Thus, in some embodiments, the light chain variable region of the TREM2 agonist antigen binding protein comprises a sequence that is at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, or at least 95% identical to a sequence selected from SEQ ID NO: 46-63. In some embodiments, the TREM2 agonist antigen binding protein may comprise a light chain variable region from any engineered anti-TREM2 antibody variant listed in Tables 2A-2F below.

[0139] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO:54 having a mutation at one or more amino acid positions 64, 79, 80, 85, 94, and / or 100. In some such embodiments, the mutation is V64G, V64A, Q79E, Q79D, S80P, S80A, F85V, F85L, F85A, F85D, F85I, F85L, F85M, F85T, W94F, W94Y, W94S, W94T, W94A, W94H, W94I, W94Q, P100R, P100Q, P100G, or a combination thereof. In another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 55 having a mutation at one or more amino acid positions 64, 79, 80, 94, and / or 100. Such mutations may include V64G, V64A, Q79E, Q79D, S80P, S80A, W94F, W94Y, W94S, W94T, W94A, W94H, W94I, W94Q, P100R, P100Q, P100G, or a combination thereof. In certain embodiments, the mutation is V64G, V64A, Q79E, S80P, S80A, W94Y, W94S, P100R, P100Q, or a combination thereof. In another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO:60 having mutations at one or more amino acid positions 60, 92, and / or 93. The mutations in such embodiments may be selected from L60S, L60P, L60D, L60A, D92E, D92Q, D92T, D92N, S93A, S93N, S93Q, S93V, or a combination thereof. In another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO:61 having mutations at one or more amino acid positions 56, 57, 92, and / or 93. In such embodiments, the mutation can be N56S, N56T, N56Q, N56E, G57A, G57V, D92E, D92Q, D92T, D92N, S93A, S93N, S93Q, S93V, or a combination thereof. In certain embodiments, the mutation is N56S, N56Q, G57A, D92E, D92Q, S93A, or a combination thereof. In yet another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 62 having mutations at amino acid positions 36, 46, 61, and / or 100.Such mutations may include F36Y, S46L, S46R, S46V, S46F, K61R, P100Q, P100G, P100R, or a combination thereof. In a specific embodiment, the mutation is F36Y, K61R, P100Q, or a combination thereof. In another embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO:52 having a mutation at amino acid position 91, the mutation may be selected from F91V, F91I, F91T, F91L, or F91D. In one embodiment, the mutation is F91V.

[0140] In some embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region that is a variant of a heavy chain variable region from any anti-TREM2 antibody described herein. Thus, in some embodiments, the heavy chain variable region of the TREM2 agonist antigen binding protein comprises a sequence selected from SEQ ID NO: 110-126 that is at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, or at least 95% identical. For example, the TREM2 agonist antigen binding protein may comprise a heavy chain variable region from any engineered anti-TREM2 antibody variant listed in Tables 2A-2F below. In one embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence having mutations at one or more amino acid positions 19, 55, 56, 57, 58, and / or 104 of SEQ ID NO: 117. In some such embodiments, the mutation is M19K, M19R, M19T, M19E, M19N, M19Q, D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, W104F, W104Y, W104T, W104S, W104A, W104H, W104I, W104Q, or a combination thereof. In another embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 118 having a mutation at one or more amino acid positions 19, 55, 56, 57, 58, and / or 104. Such mutations may include M19K, M19R, M19T, M19E, M19N, M19Q, D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, W104F, W104Y, W104T, W104S, W104A, W104H, W104I, W104Q, or a combination thereof. In certain embodiments, the mutation is M19K, D55E, S56A, D57E, T58A, W104Y, W104T, or a combination thereof. In another embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 123 having a mutation at one or more amino acid positions 27, 55, 56, 57, 58, 105 and / or 106.In some embodiments, the mutation is selected from H27Y, H27D, H27F, H27N, D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, D105E, D105Q, D105T, D105N, D105G, S106A, S106Q, S106V, S106T, or a combination thereof. In yet another embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 124 having mutations at one or more amino acid positions 55, 56, 57, 58, 105, and / or 106. The mutation in such embodiments can be selected from D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, D105E, D105Q, D105T, D105N, D105G, S106A, S106Q, S106V, S106T or a combination thereof. In certain embodiments, the mutation is D55E, D55Q, S56A, D57E, T58A, D105E, D105N, S106A or a combination thereof. In still another embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence having a mutation at one or more amino acid positions 43, 76, 85, 99, 100 and / or 116 of SEQ ID NO: 125. Such mutations may include L43Q, L43K, L43H, I76T, R85S, R85G, R85N, R85D, D99E, D99Q, D99S, D99T, G100A, G100Y, G100V, T116L, T116M, T116P, T116R, or a combination thereof. In certain embodiments, the mutation is L43Q, R85S, D99E, G100A, G100Y, T116L, or a combination thereof. In another embodiment, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence having a mutation at amino acid position 62 and / or 63 of SEQ ID NO: 115. In such embodiments, the mutation may be selected from D62E, D62Q, D62T, D62N, S63A, S63Q, S63V, or a combination thereof. In some embodiments, the mutation is D62E, D62Q, S63A, or a combination thereof.In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and / or a heavy chain variable region from any of the anti-TREM2 variant antibodies listed in Tables 2A, 2B, 3A, 3B, and 19.Thus, in some embodiments, the light chain variable region of the TREM2 agonist antigen binding protein comprises a sequence at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, or at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 61, 153-162, and 295-300. In these and other embodiments, the heavy chain variable region of the TREM2 agonist antigen binding protein comprises a sequence at least 90% identical, at least 91% identical, at least 92% identical, at least 93% identical, at least 94% identical, or at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 124, 180-190, and 307-312.

[0141] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO:54 having a mutation at one or more amino acid positions 64, 79, 80, 85, 94, and / or 100. Such mutations may include V64G, V64A, Q79E, Q79D, S80P, S80A, F85V, F85L, F85A, F85D, F85I, F85L, F85M, F85T, W94F, W94Y, W94S, W94T, W94A, W94H, W94I, W94Q, P100R, P100Q, P100G, or a combination thereof. In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 117 having a mutation at one or more amino acid positions 19, 55, 56, 57, 58, and / or 104. In certain embodiments, the mutation is selected from M19K, M19R, M19T, M19E, M19N, M19Q, D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, W104F, W104Y, W104T, W104S, W104A, W104H, W104I, W104Q, or a combination thereof.

[0142] In other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 55 having a mutation at one or more amino acid positions 64, 79, 80, 94, and / or 100. In some embodiments, the mutation is selected from V64G, V64A, Q79E, Q79D, S80P, S80A, W94F, W94Y, W94S, W94T, W94A, W94H, W94I, W94Q, P100R, P100Q, P100G, or a combination thereof. In certain embodiments, the mutation is selected from V64G, V64A, Q79E, S80P, S80A, W94Y, W94S, P100R, P100Q, or a combination thereof. For example, in some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 55 having one or more mutations selected from V64G, Q79E, S80P, W94Y, and P100Q. In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 118 having mutations at one or more amino acid positions 19, 55, 56, 57, 58, and / or 104. Such mutations may include M19K, M19R, M19T, M19E, M19N, M19Q, D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, W104F, W104Y, W104T, W104S, W104A, W104H, W104I, W104Q, or a combination thereof. In certain embodiments, the mutation is selected from M19K, D55E, S56A, D57E, T58A, W104Y, W104T, or a combination thereof.

[0143] In certain other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 60 having mutations at one or more amino acid positions 60, 92, and / or 93. The mutations may be selected from L60S, L60P, L60D, L60A, D92E, D92Q, D92T, D92N, S93A, S93N, S93Q, S93V, or a combination thereof. In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 123 having mutations at one or more amino acid positions 27, 55, 56, 57, 58, 105, and / or 106. In some embodiments, the mutation is selected from H27Y, H27D, H27F, H27N, D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, D105E, D105Q, D105T, D105N, D105G, S106A, S106Q, S106V, S106T, or a combination thereof.

[0144] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 61 having mutations at one or more amino acid positions 56, 57, 92, and / or 93. In certain embodiments, the mutations are selected from N56S, N56T, N56Q, N56E, G57A, G57V, D92E, D92Q, D92T, D92N, S93A, S93N, S93Q, S93V, or a combination thereof. In some embodiments, the mutations are selected from N56S, N56Q, G57A, D92E, D92Q, S93A, or a combination thereof. In a specific embodiment, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 61 having one or more mutations selected from N56S, D92E, and S93A. In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 124 having a mutation at one or more amino acid positions 55, 56, 57, 58, 105, and / or 106. The mutation may be selected from D55E, D55Q, D55N, D55T, S56A, S56Q, S56V, D57S, D57E, D57Q, T58A, T58V, D105E, D105Q, D105T, D105N, D105G, S106A, S106Q, S106V, S106T, or a combination thereof. In certain embodiments, the mutation is D55E, D55Q, S56A, D57E, T58A, D105E, D105N, S106A, or a combination thereof. In some embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 124 having one or more mutations selected from D55E, S56A, D57E, D105E, and S106A.

[0145] In other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence of SEQ ID NO: 62 having mutations at amino acid positions 36, 46, 61, and / or 100. In specific embodiments, the mutation is selected from F36Y, S46L, S46R, S46V, S46F, K61R, P100Q, P100G, P100R, or a combination thereof. In some embodiments, the mutation is F36Y, K61R, P100Q, or a combination thereof. In some embodiments, the mutation is S46L, P100Q, or a combination thereof. In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence of SEQ ID NO: 125 having mutations at one or more amino acid positions 43, 76, 85, 99, 100, and / or 116. Mutation can be selected from L43Q, L43K, L43H, I76T, R85S, R85G, R85N, R85D, D99E, D99Q, D99S, D99T, G100A, G100Y, G100V, T116L, T116M, T116P, T116R or a combination thereof. In certain embodiments, mutation is L43Q, I76T, R85S, D99E, G100A, G100Y, T116L or a combination thereof.

[0146] In still other embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising a sequence having a mutation at amino acid position 91 of SEQ ID NO:52. The mutation may be selected from F91V, F91I, F91T, F91L, or F91D. In one embodiment, the mutation is F91V. In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising a sequence having a mutation at amino acid position 62 and / or 63 of SEQ ID NO:115. In specific embodiments, the mutation is selected from D62E, D62Q, D62T, D62N, S63A, S63Q, S63V, or a combination thereof. In some embodiments, the mutation is selected from D62E, D62Q, S63A, or a combination thereof.

[0147] Table 2A. Engineered variants of 10E3 antibody

[0148]

[0149] Table 2B. Engineered variants of 13E7 antibody

[0150]

[0151]

[0152] Table 2C. Engineered variants of 4C5 antibody

[0153]

[0154] Table 2D. Engineered variants of 6E7 antibody

[0155]

[0156] Table 2E. Engineered variants of 5E3 antibody

[0157]

[0158] Table 2F. Engineered variants of 24G6 antibody

[0159]

[0160] In some embodiments, the TREM2 agonist antigen binding protein comprises one or more CDRs of a variant of an anti-TREM2 antibody described herein. In some embodiments, the TREM2 agonist antigen binding protein may comprise one or more CDRs of an anti-TREM2 antibody variant listed in Tables 3A, 3B, 3C, 3D, and 3E below.

[0161] In certain embodiments, the TREM2 agonist antigen binding proteins of the present invention comprise a light chain variable region and / or a heavy chain variable region from an affinity-modulated variant of the 6E7 antibody. For example, in some embodiments, the TREM2 agonist antigen binding proteins comprise a light chain variable region and / or a heavy chain variable region having one or more amino acid substitutions listed in Table 2G.

[0162] Table 2G. 6E7 antibody affinity modulating variants

[0163]

[0164]

[0165]

[0166] Binding signal values ​​marked with an * were obtained with 110 nM Ab concentration, whereas the remaining values ​​in the column were obtained with 10 nM Ab concentration.

[0167] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the sequence of SEQ ID NO: 61 having a mutation at one or more amino acid positions 24, 31, 50, 52, 54, 56, 89, 92, 93, 94, and / or 96. In certain embodiments, the mutation is selected from R24A, S31R, A50S, A50G, S52G, L54R, N56K, N56R, N56L, N56T, Q89G, D92V, S93R, F94Y, F94L, R96H, R96L, or a combination thereof. In these and other embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 124 having a mutation at one or more amino acid positions 27, 28, 30, 32, 50, 54, 58, 60, 61, 63, 66, 99, 101, 103, 104, and / or 110. In some embodiments, the mutation is selected from Y27S, S28G, S28H, T30N, T30G, T30E, T30A, Y32E, I50T, G54S, T58V, Y60L, S61A, S63G, S63E, G66D, Q99G, Q99S, Q99M, T101G, Y103R, Y104G, F110S, or a combination thereof. The amino acid sequences of the light chain and heavy chain variable regions and the associated CDRs of the exemplary 6E7 antibody variants with improved affinity are shown in Tables 3A and 3B below, respectively. The amino acid sequences of the light chain and heavy chain variable regions and the associated CDRs of the exemplary 6E7 antibody variants with reduced affinity are shown in Tables 3C and 3D below, respectively. The corresponding sequences of the 6E7 antibody are listed for comparison.

[0168] Table 3A. Light chain variable region amino acid sequences of TREM2 antibodies for affinity improvement

[0169]

[0170]

[0171] Table 3B. Heavy chain variable region amino acid sequences of TREM2 antibodies for affinity improvement

[0172]

[0173]

[0174]

[0175] In some embodiments, the TREM2 agonist antigen binding protein of the present invention may comprise one or more CDRs from the affinity-enhanced variants presented in Tables 3A (light chain CDRs; i.e., CDRL) and 3B (heavy chain CDRs, i.e., CDRH). In some embodiments, the TREM2 agonist antigen binding protein comprises a consensus CDR sequence derived from an affinity-enhanced variant. For example, in some embodiments, the TREM2 agonist antigen binding protein comprises the CDRL2 consensus sequence X1ASSX2QX3 (SEQ ID NO: 139), wherein X1 is A or G; X2 is L or R; and X3 is N, K, R, L, or T. In another embodiment, the TREM2 agonist antigen binding protein comprises the CDRL3 consensus sequence X1QADX2X3PX4T (SEQ ID NO: 140), wherein X1 is Q or G; X2 is S or R; X3 is F, L, or Y; and X4 is R or H. In yet another embodiment, the TREM2 agonist antigen binding protein comprises the CDRH2 consensus sequence X1IYPGDSDX2RX3X4PX5FQX6 (SEQ ID NO: 141), wherein X1 is I or T; X2 is T or V; X3 is Y or L; X4 is S or A; X5 is S, G or E; and X6 is G or D. In some embodiments, the TREM2 agonist antigen binding protein comprises the CDRH3 consensus sequence X1RTFYYDSSDYX2DY (SEQ ID NO: 142), wherein X1 is Q, G, S or M; and X2 is F or S.

[0176] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, the heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3, wherein CDRL1 comprises the sequence of SEQ ID NO: 16, CDRL2 comprises the consensus sequence of SEQ ID NO: 139, CDRL3 comprises the consensus sequence of SEQ ID NO: 140, CDRH1 comprises the sequence of SEQ ID NO: 85, CDRH2 comprises the consensus sequence of SEQ ID NO: 141, and CDRH3 comprises the consensus sequence of SEQ ID NO: 142.

[0177] In some embodiments, the TREM2 agonist antigen binding protein comprises a CDRL1 comprising a sequence of SEQ ID NO: 16; a CDRL2 comprising a sequence selected from SEQ ID NOs: 26 and 143-147; a CDRL3 comprising a sequence selected from SEQ ID NOs: 43 and 148-152; a CDRH1 comprising a sequence of SEQ ID NO: 85; a CDRH2 comprising a sequence selected from SEQ ID NOs: 91 and 170-175; and a CDRH3 comprising a sequence selected from SEQ ID NOs: 176-179.

[0178] In certain embodiments, a TREM2 agonist antigen binding protein of the invention comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein:

[0179] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 143 and 148, respectively;

[0180] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 144 and 149, respectively;

[0181] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 145 and 43, respectively;

[0182] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 146 and 148, respectively;

[0183] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 26 and 150, respectively;

[0184] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 143 and 151, respectively;

[0185] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 145 and 148, respectively;

[0186] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 145 and 152, respectively;

[0187] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 144 and 43, respectively; or

[0188] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 147 and 43, respectively.

[0189] In related embodiments, a TREM2 agonist antigen binding protein of the invention comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0190] (a) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 170 and 176, respectively;

[0191] (b) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 171 and 177, respectively;

[0192] (c) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 172 and 177, respectively;

[0193] (d) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 171 and 178, respectively;

[0194] (e) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 171 and 179, respectively;

[0195] (f) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 173 and 177, respectively;

[0196] (g) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 176, respectively;

[0197] (h) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 174 and 176, respectively;

[0198] (i) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 175 and 178, respectively; or

[0199] (j) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 178, respectively.

[0200] In some embodiments, a TREM2 agonist antigen binding protein of the invention comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0201] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 143 and 148, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 170 and 176, respectively;

[0202] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 144 and 149, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 171 and 177, respectively;

[0203] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 145 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 172 and 177, respectively;

[0204] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 146 and 148, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 171 and 178, respectively;

[0205] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 26 and 150, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 171 and 179, respectively;

[0206] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 143 and 151, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 173 and 177, respectively;

[0207] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 145 and 148, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 176, respectively;

[0208] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 145 and 152, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 171 and 178, respectively;

[0209] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 143 and 151, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 174 and 176, respectively;

[0210] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 144 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 175 and 178, respectively; or

[0211] (k) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 147 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 178, respectively.

[0212] In some embodiments, a TREM2 agonist antigen binding protein of the invention may comprise a light chain variable region selected from LV-101, LV-102, LV-103, LV-104, LV-105, LV-106, LV-107, LV-108, LV-109, and LV-110 as shown in Table 3A, and / or a heavy chain variable region selected from HV-101, HV-102, HV-103, HV-104, HV-105, HV-106, HV-107, HV-108, HV-109, HV-110, and HV-111 as shown in Table 3B, or a sequence that is at least 80% identical, at least 85% identical, at least 90% identical, or at least 95% identical to any of the sequences in Tables 3A and 3B. For example, in some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising (i) a sequence at least 90% identical to a sequence selected from SEQ ID NOs: 153-162, (ii) a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 153-162, or (iii) a sequence selected from SEQ ID NOs: 153-162. In related embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising (i) a sequence at least 90% identical to a sequence selected from SEQ ID NOs: 180-190, (ii) a sequence at least 95% identical to a sequence selected from SEQ ID NOs: 180-190, or (iii) a sequence selected from SEQ ID NOs: 180-190.

[0213] Each light chain variable region listed in Table 3A can be combined with any heavy chain variable region listed in Table 3B to form an anti-TREM2 binding domain of an antigen binding protein of the invention. Examples of such combinations include, but are not limited to, LV-101 (SEQ ID NO: 153) and HV-101 (SEQ ID NO: 180); LV-102 (SEQ ID NO: 154) and HV-102 (SEQ ID NO: 181); LV-103 (SEQ ID NO: 155) and HV-103 (SEQ ID NO: 182); LV-104 (SEQ ID NO: 156) and HV-104 (SEQ ID NO: 183); LV-105 (SEQ ID NO: 157) and HV-105 (SEQ ID NO: 184); LV-106 (SEQ ID NO: 158) and HV-106 (SEQ ID NO: 185); LV-107 (SEQ ID NO: 159) and HV-107 (SEQ ID NO: 186); LV-108 (SEQ ID NO: 189); NO: 160) and HV-108 (SEQ ID NO: 187); LV-106 (SEQ ID NO: 158) and HV-109 (SEQ ID NO: 188); LV-109 (SEQ ID NO: 161) and HV-110 (SEQ ID NO: 189); and LV-110 (SEQ ID NO: 162) and HV-111 (SEQ ID NO: 190).

[0214] Table 3C. Light chain variable region amino acid sequences for TREM2 antibodies with reduced affinity

[0215]

[0216] Table 3D. Heavy chain variable region amino acid sequences for TREM2 antibodies with reduced affinity

[0217]

[0218]

[0219] In some embodiments, the TREM2 agonist antigen binding protein of the present invention may include one or more CDRs from the variants with reduced affinity presented in Table 3C (light chain CDR; i.e., CDRL) and Table 3D (heavy chain CDR, i.e., CDRH). In some embodiments, the TREM2 agonist antigen binding protein comprises a consensus CDR sequence derived from a variant with reduced affinity. For example, in one embodiment, the TREM2 agonist antigen binding protein comprises a CDRL1 consensus sequence X1ASQGISX2WLA (SEQID NO: 284), wherein X1 is R or A; and X2 is S or R. In another embodiment, the TREM2 agonist antigen binding protein comprises a CDRL2 consensus sequence X1AX2SLQN (SEQ ID NO: 285), wherein X1 is A or S; and X2 is S or G. In another embodiment, the TREM2 agonist antigen binding protein comprises a CDRL3 consensus sequence QQAX1SFPX2T (SEQ ID NO: 286), wherein X1 is D or V; and X2 is R or L. In another embodiment, the TREM2 agonist antigen binding protein comprises the CDRH1 consensus sequence SX1WIA (SEQ ID NO: 287), wherein X1 is Y or E. In yet another embodiment, the TREM2 agonist antigen binding protein comprises the CDRH2 consensus sequence IIYPX1DSDTRYSPSFQG (SEQ ID NO: 288), wherein X1 is G or S. In yet another embodiment, the TREM2 agonist antigen binding protein comprises the CDRH3 consensus sequence QRX1FX2X3DSSDYFDY (SEQ ID NO: 289), wherein X1 is T or G; X2 is Y or R; and X3 is Y or G. In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising complementarity determining regions CDRL1, CDRL2 and CDRL3, the heavy chain variable region comprising complementarity determining regions CDRH1, CDRH2 and CDRH3, wherein CDRL1 comprises the sequence of SEQ ID NO:284, CDRL2 comprises the consensus sequence of SEQ ID NO:285, CDRL3 comprises the consensus sequence of SEQ ID NO:286, CDRH1 comprises the sequence of SEQ ID NO:287, CDRH2 comprises the consensus sequence of SEQ ID NO:288, and CDRH3 comprises the consensus sequence of SEQ ID NO:289.

[0220] In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a CDRL1 comprising a sequence selected from SEQ ID NOs: 16, 290, and 291; a CDRL2 comprising a sequence selected from SEQ ID NOs: 28, 292, and 293; a CDRL3 comprising a sequence selected from SEQ ID NOs: 43, 294, and 271; a CDRH1 comprising a sequence of SEQ ID NO: 85 or SEQ ID NO: 302; a CDRH2 comprising a sequence of SEQ ID NO: 91 or SEQ ID NO: 303; and a CDRH3 comprising a sequence selected from SEQ ID NOs: 107 and 304-306.

[0221] In some embodiments, a TREM2 agonist antigen binding protein of the invention comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein:

[0222] (a) CDRL1, CDRL2 and CDRL3 have sequences of SEQ ID NOs: 16, 28 and 43, respectively;

[0223] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 292 and 43, respectively;

[0224] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 294, respectively;

[0225] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 290, 28 and 43, respectively;

[0226] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 293 and 43, respectively;

[0227] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 271, respectively; or

[0228] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 291, 28 and 43, respectively.

[0229] In related embodiments, a TREM2 agonist antigen binding protein of the invention comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0230] (a) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 304, respectively;

[0231] (b) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0232] (c) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 305, respectively;

[0233] (d) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 303 and 107, respectively;

[0234] (e) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 306, respectively; or

[0235] (f) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 302, 91 and 107, respectively.

[0236] In some embodiments, a TREM2 agonist antigen binding protein of the invention comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0237] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 304, respectively;

[0238] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 292 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0239] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 294, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0240] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0241] (e) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 305, respectively;

[0242] (f) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 303 and 107, respectively;

[0243] (g) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 290, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0244] (h) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 306, respectively;

[0245] (i) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 293 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively;

[0246] (j) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 28 and 271, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 91 and 107, respectively; or

[0247] (k) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 291, 28 and 43, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 302, 91 and 107, respectively.

[0248] In some embodiments, the TREM2 agonist antigen binding protein of the present invention may comprise a light chain variable region selected from LV-16, LV-201, LV-202, LV-203, LV-204, LV-205, and LV-206 as shown in Table 3C, and / or a heavy chain variable region selected from HV-15, HV-201, HV-202, HV-203, HV-204, HV-205, and HV-206 as shown in Table 3D, or a sequence that is at least 80% identical, at least 85% identical, at least 90% identical, or at least 95% identical to any of the sequences in Tables 3C and 3D. For example, in certain embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising (i) a sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 61 and 295-300, (ii) a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 61 and 295-300, or (iii) a sequence selected from the group consisting of SEQ ID NOs: 61 and 295-300. In related embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising (i) a sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NOs: 124 and 307-312, (ii) a sequence at least 95% identical to a sequence selected from the group consisting of SEQ ID NOs: 124 and 307-312, or (iii) a sequence selected from the group consisting of SEQ ID NOs: 124 and 307-312.

[0249] In some embodiments, each light chain variable region listed in Table 3C can be combined with any heavy chain variable region listed in Table 3D to form an anti-TREM2 binding domain of an antigen binding protein of the invention. Examples of such combinations include, but are not limited to: LV-16 (SEQ ID NO: 61) and HV-201 (SEQ ID NO: 307); LV-201 (SEQ ID NO: 295) and HV-15 (SEQ ID NO: 124); LV-202 (SEQ ID NO: 296) and HV-15 (SEQ ID NO: 124); LV-16 (SEQ ID NO: 61) and HV-202 (SEQ ID NO: 308); LV-16 (SEQ ID NO: 61) and HV-203 (SEQ ID NO: 309); LV-16 (SEQ ID NO: 61) and HV-204 (SEQ ID NO: 310); LV-203 (SEQ ID NO: 297) and HV-15 (SEQ ID NO: 124); LV-16 (SEQ ID NO: 61) and HV-205 (SEQ ID NO: 311). NO:311); LV-204 (SEQ ID NO:298) and HV-15 (SEQ ID NO:124); LV-205 (SEQ ID NO:299) and HV-15 (SEQ ID NO:124); and LV-206 (SEQ ID NO:300) and HV-206 (SEQ ID NO:312).

[0250] In some embodiments, the TREM2 agonist antigen binding protein comprises one or more CDRs of the anti-TREM2 antibody variants listed in Table 3E. In some embodiments, the TREM2 agonist antigen binding protein comprises the light chain variable region and the heavy chain variable region of the anti-TREM2 antibody variants listed in Table 3E.

[0251] Table 3E. Exemplary variable region amino acid sequences of engineered antibodies

[0252]

[0253]

[0254] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3, wherein:

[0255] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 369 and 370, respectively;

[0256] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 372, respectively; or

[0257] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 21 and 33, respectively; (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 357, 20 and 33, respectively.

[0258] In some embodiments, the TREM2 agonist antigen binding protein comprises a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0259] (a) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 368 and 98, respectively;

[0260] (b) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 371 and 107, respectively;

[0261] (c) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 373 and 374, respectively; or

[0262] (d) CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 86, 94 and 375, respectively.

[0263] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising CDRL1, CDRL2, and CDRL3 and a heavy chain variable region comprising CDRH1, CDRH2, and CDRH3, wherein:

[0264] (a) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 359, 22 and 35, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 77, 368 and 98, respectively;

[0265] (b) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 16, 369 and 370, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 85, 371 and 107, respectively;

[0266] (c) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 372, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 373 and 374, respectively; or

[0267] (d) CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 17, 29 and 44, respectively, and CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 86, 94 and 375, respectively.

[0268] Thus, in some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDRL1, CDRL2 and CDRL3, the heavy chain variable region comprising CDRH1, CDRH2 and CDRH3, wherein the CDRL1, CDRL2 and CDRL3 have the sequences of SEQ ID NOs: 361, 23 and 372, respectively, and the CDRH1, CDRH2 and CDRH3 have the sequences of SEQ ID NOs: 81, 373 and 374, respectively.

[0269] Thus, in some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising CDRL1, CDRL2, and CDRL3 having sequences of SEQ ID NOs: 361, 23, and 372, respectively, and CDRH1, CDRH2, and CDRH3 having sequences of SEQ ID NOs: 81, 373, and 374, respectively. In certain embodiments, the antibody is human. In some embodiments, the TREM2 agonist antigen binding protein comprises

[0270] (a) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 326 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 327;

[0271] (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 328 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 329;

[0272] (c) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 330 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 331; or

[0273] (d) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 332 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 333.

[0274] In some embodiments, the TREM2 agonist antigen binding protein comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:330 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:331.

[0275] Thus, in some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 330 and a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 331. In certain embodiments, the antibody is human.

[0276] In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 326, 328, 330, or 332. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a heavy chain variable region consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 327, 329, 331, or 333. In specific embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 326, and the heavy chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 327. In specific embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 328, and the heavy chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 329. In a specific embodiment, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 330, and the heavy chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 331. In a specific embodiment, the TREM2 agonist antigen binding protein of the present invention comprises a light chain variable region and a heavy chain variable region, wherein the light chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 332, and the heavy chain variable region consists of or consists essentially of the amino acid sequence of SEQ ID NO: 333.

[0277] In some embodiments, each light chain variable region disclosed in Tables 1A, 3A, 3C and 3E and each heavy chain variable region disclosed in Tables 1B, 3B, 3D and 3E can be connected to a light chain constant region (Table 4) and a heavy chain constant region (Table 5) to form a complete antibody light chain and heavy chain, as discussed further below. In addition, each heavy chain and light chain sequence produced can be combined to form a complete antibody structure. It should be understood that the heavy chain and light chain variable regions provided herein can also be connected to other constant domains having sequences different from the exemplary sequences listed herein.

[0278] In some embodiments, exemplary TREM2 agonist antibodies having a light chain variable region with a light chain constant region and a heavy chain variable region with a heavy chain constant region are disclosed in Table 3F.

[0279] Table 3F. Light and heavy chain amino acid sequences of exemplary antibodies

[0280]

[0281]

[0282]

[0283]

[0284] In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 334 and a heavy chain comprising the sequence of SEQ ID NO: 335. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 334 and a heavy chain comprising the sequence of SEQ ID NO: 336. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 337 and a heavy chain comprising the sequence of SEQ ID NO: 338. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 339 and a heavy chain comprising the sequence of SEQ ID NO: 340. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 341 and a heavy chain comprising the sequence of SEQ ID NO: 342. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 343 and a heavy chain comprising the sequence of SEQ ID NO: 344. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 343 and a heavy chain comprising the sequence of SEQ ID NO: 345. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 346 and a heavy chain comprising the sequence of SEQ ID NO: 347. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 348 and a heavy chain comprising the sequence of SEQ ID NO: 349. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain comprising the sequence of SEQ ID NO: 350 and a heavy chain comprising the sequence of SEQ ID NO: 351.

[0285] In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 334 and a heavy chain comprising the sequence of SEQ ID NO: 335. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 334 and a heavy chain comprising the sequence of SEQ ID NO: 336. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 337 and a heavy chain comprising the sequence of SEQ ID NO: 338. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 339 and a heavy chain comprising the sequence of SEQ ID NO: 340. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 341 and a heavy chain comprising the sequence of SEQ ID NO: 342. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 343 and a heavy chain comprising the sequence of SEQ ID NO: 344. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 343 and a heavy chain comprising the sequence of SEQ ID NO: 345.In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 346 and a heavy chain comprising the sequence of SEQ ID NO: 347. Thus, in some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 348 and a heavy chain comprising the sequence of SEQ ID NO: 349. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 350 and a heavy chain comprising the sequence of SEQ ID NO: 351. In some embodiments, the present invention provides a method of treating ALSP in a human patient, the method comprising administering to the patient an effective amount of a TREM2 agonist antigen binding protein comprising a light chain comprising the sequence of SEQ ID NO: 352 and a heavy chain comprising the sequence of SEQ ID NO: 353.

[0286] In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 334, 337, 339 or 341. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 343, 346, 348 or 350. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a heavy chain consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 335, 336, 338, 340 or 342. In some embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a heavy chain consisting of or consisting essentially of the amino acid sequence of SEQ ID NO: 344, 345, 347, 349 or 351. In specific embodiments, the TREM2 agonist antigen binding protein of the present invention comprises a light chain and a heavy chain, wherein:

[0287] (a) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 334, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 335;

[0288] (b) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 334, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 336;

[0289] (c) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 337, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 338;

[0290] (d) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 339, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 340; or

[0291] (e) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 341, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 342.

[0292] In a specific embodiment, the TREM2 agonist antigen binding protein of the invention comprises a light chain and a heavy chain, wherein:

[0293] (a) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 343, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 344;

[0294] (b) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 343, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 345;

[0295] (c) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 346, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 347;

[0296] (d) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 348, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 349;

[0297] (e) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 350, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO: 351; or

[0298] (f) the light chain consists of or consists essentially of the amino acid sequence of SEQ ID NO:352, and the heavy chain consists of or consists essentially of the amino acid sequence of SEQ ID NO:353.

[0299] Unless otherwise indicated, referring to a specific sequence in Table 1A, 1B, 3A, 3B, 3C, 3D, 3E and the related discussion, the numbering of amino acid residues in the immunoglobulin heavy or light chain is according to the Kabat-EU numbering, as described in the following documents: Kabat et al., Sequences of Proteins of Immunological Interest, 5th Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, pp. 662, 680, 689 (1991), and Edelman et al., Proc. Natl. Acad. USA, Vol. 63: 78-85 (1969). When referring to the position of amino acids in the variable region, the Kabat numbering scheme is generally used, whereas when referring to the position of amino acids in the immunoglobulin constant region, the EU numbering scheme is generally used.

[0300] In some embodiments, the TREM2 antigen binding protein comprises an antibody that competes with an antibody comprising a CDRL1, CDRL2, CDRL3, or light chain variable region disclosed in Tables 1A, 3A, 3C, and 3E and a heavy chain variable region disclosed in Tables 1B, 3B, 3D, and 3E. In some embodiments, a suitable assay for detecting competitive binding employs The kinetic sensor used with the system (PallForteBio) measures binding interactions using a biolayer interferometry method. A group of antibodies (i.e., antibodies 10E3, 13E7, 24F4, 4C5, 4G10, 32E3, and 6E7) compete with each other for binding to human TREM2, indicating that they share the same or similar epitopes on human TREM2. Antibodies 16B8, 26A10, 26C10, 26F2, 33B12, and 5E3 compete with each other for TREM2 binding, but do not compete with antibodies in the first group or antibodies 24A10, 24G6, or 25F12, indicating that the antibodies of the second group bind to different epitopes on human TREM2. Antibodies 24A10 and 24G6 share similar epitopes on human TREM2 because the two antibodies compete with each other for human TREM2 binding, but do not compete with any other antibodies. Antibody 25F12 does not compete with any other tested antibodies for human TREM2 binding, indicating that the antibody binds to another epitope.

[0301] In some embodiments, the TREM2 agonist antigen binding protein competes with a reference antibody for binding to human TREM2, wherein the reference antibody comprises a light chain variable region containing a sequence selected from SEQ ID NOs: 46-63 and a heavy chain variable region containing a sequence selected from SEQ ID NOs: 110-126. In other embodiments, the TREM2 agonist antigen binding protein of the present invention competes with a reference antibody for binding to human TREM2, wherein the reference antibody comprises a light chain variable region containing a sequence selected from SEQ ID NOs: 153-162 and a heavy chain variable region containing a sequence selected from SEQ ID NOs: 180-190. In still other embodiments, the TREM2 agonist antigen binding protein of the present invention competes with a reference antibody for binding to human TREM2, wherein the reference antibody comprises a light chain variable region containing a sequence selected from SEQ ID NOs: 61 and 295-300 and a heavy chain variable region containing a sequence selected from SEQ ID NOs: 124 and 307-312. In certain embodiments, the TREM2 agonist antigen binding proteins of the invention compete for binding to human TREM2 with one or more anti-TREM2 antibodies described herein, including 12G10, 26A10, 26C10, 26F2, 33B12, 24C12, 24G6, 24A10, 10E3, 13E7, 14C12, 25F12, 32E3, 24F4, 16B8, 4C5, 6E7, 5E3, 4G10, V3, V9, V10, V23, V24, V27, V30, V33, V40, V44, V48, V49, V52, V57, V60, V68, V70, V73, V76, V83, V84, and V90.

[0302] In some embodiments, the TREM2 agonist antigen binding protein competes with a reference antibody for binding to human TREM2, wherein the reference antibody comprises a light chain variable region comprising the sequence of SEQ ID NO: 61 and a heavy chain variable region comprising the sequence of SEQ ID NO: 124. In such embodiments, the antigen binding protein that competes with the reference antibody for binding to human TREM2 will bind to the same or similar epitope as antibody 6E7 or any of the other antibodies 10E3, 13E7, 24F4, 4C5, 4G10, and 32E3.

[0303] In some embodiments, the TREM2 agonist antigen binding protein competes with a reference antibody for binding to human TREM2, wherein the reference antibody comprises a light chain variable region comprising the sequence of SEQ ID NO: 62 and a heavy chain variable region comprising the sequence of SEQ ID NO: 125. In such embodiments, the antigen binding protein that competes with the reference antibody for binding to human TREM2 will bind to the same or similar epitope as antibody 5E3 or any of the other antibodies 16B8, 26A10, 26C10, 26F2, and 33B12.

[0304] In some embodiments, the TREM2 agonist antigen binding protein competes with a reference antibody for binding to human TREM2, wherein the reference antibody comprises a light chain variable region comprising the sequence of SEQ ID NO: 52 and a heavy chain variable region comprising the sequence of SEQ ID NO: 115. In such embodiments, the antigen binding protein that competes with the reference antibody for binding to human TREM2 will bind to the same or a similar epitope as antibody 24G6 or antibody 24A10.

[0305] In some embodiments, the TREM2 agonist antigen binding protein competes with a reference antibody for binding to human TREM2, wherein the reference antibody comprises a light chain variable region comprising the sequence of SEQ ID NO: 56 and a heavy chain variable region comprising the sequence of SEQ ID NO: 119. In such embodiments, the antigen binding protein that competes with the reference antibody for binding to human TREM2 will bind to the same or a similar epitope as antibody 25F12.

[0306] In some embodiments, isolated nucleic acids encoding anti-TREM2 binding domains of antigen binding proteins of the invention can be used to synthesize antigen binding proteins or to generate variants. In some embodiments, the polynucleotides may comprise a nucleotide sequence that is at least 80% identical, at least 90% identical, at least 95% identical, or at least 98% identical to any of the nucleotide sequences listed in Table 3G.

[0307] Table 3G. Exemplary anti-TREM2 antibody variable region nucleic acid sequences

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320] In some embodiments, the isolated nucleic acid encoding the anti-TREM2 antibody light chain variable region comprises a sequence that is at least 80% identical, at least 90% identical, at least 95% identical, or at least 98% identical to a sequence selected from SEQ ID NOs: 208-236 and 313-318. In certain embodiments, the isolated nucleic acid encoding the anti-TREM2 antibody light chain variable region comprises a sequence selected from SEQ ID NOs: 208-236 and 313-318. In related embodiments, the isolated nucleic acid encoding the anti-TREM2 antibody heavy chain variable region comprises a sequence that is at least 80% identical, at least 90% identical, at least 95% identical, or at least 98% identical to a sequence selected from SEQ ID NOs: 237-264 and 319-325. In other related embodiments, the isolated nucleic acid encoding the anti-TREM2 antibody heavy chain variable region comprises a sequence selected from SEQ ID NOs: 237-264 and 319-325.

[0321] In some embodiments, the polynucleotide encodes a full-length light chain and a full-length heavy chain.Exemplary polynucleotide sequences are provided in Table 3F.

[0322] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering an anti-TREM2 antibody, e.g., anti-TREM2 antibody "Ab-1," to the patient. In some embodiments, the methods of the present invention comprise administering a liquid formulation as described herein to a human patient.

[0323] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset of a disease or disorder or one or more symptoms thereof, or inhibiting the progression of a disease or disorder or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to susceptible individuals before the onset of symptoms (e.g., based on a history of symptoms and / or based on genetic or other susceptibility factors). Treatment may also be continued after symptoms subside, for example to prevent or delay their recurrence.

[0324] As used herein, a patient or subject "in need of prevention," "in need of treatment," or "in need thereof" is one who, in the judgment of an appropriate medical practitioner (e.g., a physician, nurse, or nurse practitioner for humans; a veterinarian for non-human mammals), can reasonably benefit from a particular treatment or therapy.

[0325] A "therapeutically effective amount" or "therapeutically effective dose" of a drug or therapeutic agent (such as anti-TREM2 antibody "Ab-1") refers to any amount of the drug, alone or in combination with another therapeutic agent, that is capable of protecting a patient or subject from the onset of a disease (such as ALSP), or promoting disease regression (as evidenced by reducing the severity of disease symptoms, increasing the frequency and duration of disease symptom-free periods, or preventing impairment or disability caused by the disease). The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to skilled practitioners, such as human subjects during clinical trials, animal model systems predictive of efficacy in humans, or by measuring the activity of the agent in in vitro assays.

[0326] In a preferred embodiment, a therapeutically effective amount of a drug (such as an anti-TREM2 antibody "Ab-1"), used alone or in combination with another agent, can reduce the severity of at least one disease symptom, increase the frequency and duration of disease symptom-free periods, or prevent damage or disability caused by the disease. In addition, the terms "effective" and "effectiveness" with respect to treatment include pharmacological effectiveness and physiological safety. Pharmacological effectiveness refers to the ability of a drug to reduce the severity of at least one disease symptom, increase the frequency and duration of disease symptom-free periods, or prevent damage or disability caused by the disease in a patient. Physiological safety refers to the level of toxicity or other adverse physiological effects (adverse reactions) produced at the cellular, organ and / or organism level after drug administration.

[0327] As used herein, the term "therapeutically beneficial effect" or "benefit from therapy" refers to a reduction in the severity of disease symptoms, an increase in the frequency and duration of disease symptom-free periods, or the prevention of impairment or disability resulting from the disease.

[0328] In some embodiments, the anti-TREM2 antibody (e.g., "Ab-1") is administered to a human patient by intravenous infusion. In some embodiments, the intravenous infusion of the anti-TREM2 antibody "Ab-1" is up to about 5 hours, up to about 4 hours, up to about 3 hours, up to about 2 hours, or up to about 60 minutes. In some embodiments, the intravenous infusion of the anti-TREM2 antibody "Ab-1" is about 5 minutes to about 5 hours, about 5 minutes to about 4 hours, about 5 minutes to about 3 hours, about 5 minutes to about 2 hours, or about 5 minutes to about 60 minutes. In some embodiments, the intravenous infusion of the anti-TREM2 antibody "Ab-1" is about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 50 minutes, about 55 minutes, about 60 minutes, about 70 minutes, about 80 minutes, or about 90 minutes.

[0329] In some embodiments, the anti-TREM2 antibody is administered to a human patient at a dose of up to about 200 mg / kg. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient at a dose of up to about 200 mg / kg. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient at a dose of up to about 150 mg / kg. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient at a dose of up to about 100 mg / kg. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient at a dose of about 1 mg / kg to about 100 mg / kg, about 1 mg / kg to about 90 mg / kg, about 1 mg / kg to about 80 mg / kg, about 1 mg / kg to about 70 mg / kg, or about 1 mg / kg to about 60 mg / kg. In some embodiments, an anti-TREM2 antibody (e.g., "Ab-1") is administered to a human patient at a dose of about 10 mg / kg to about 100 mg / kg, about 10 mg / kg to about 90 mg / kg, about 10 mg / kg to about 80 mg / kg, about 10 mg / kg to about 70 mg / kg, about 10 mg / kg to about 60 mg / kg, about 10 mg / kg to about 50 mg / kg, about 10 mg / kg to about 40 mg / kg, about 10 mg / kg to about 30 mg / kg, or about 10 mg / kg to about 20 mg / kg. In some embodiments, an anti-TREM2 antibody (e.g., "Ab-1") is administered to a human patient at a dose of about 20 mg / kg to about 100 mg / kg, about 20 mg / kg to about 90 mg / kg, about 20 mg / kg to about 80 mg / kg, about 20 mg / kg to about 70 mg / kg, about 20 mg / kg to about 60 mg / kg, about 20 mg / kg to about 50 mg / kg, about 20 mg / kg to about 40 mg / kg, or about 20 mg / kg to about 30 mg / kg. In some embodiments, an anti-TREM2 antibody (e.g., "Ab-1") is administered to a human patient at a dose of about 30 mg / kg to about 100 mg / kg, about 30 mg / kg to about 90 mg / kg, about 30 mg / kg to about 80 mg / kg, about 30 mg / kg to about 70 mg / kg, about 30 mg / kg to about 60 mg / kg, about 30 mg / kg to about 50 mg / kg, or about 30 mg / kg to about 40 mg / kg. In some embodiments, an anti-TREM2 antibody (e.g., "Ab-1") is administered to a human patient at a dose of about 40 mg / kg to about 100 mg / kg, about 40 mg / kg to about 90 mg / kg, about 40 mg / kg to about 80 mg / kg, about 40 mg / kg to about 70 mg / kg, about 40 mg / kg to about 60 mg / kg, or about 40 mg / kg to about 50 mg / kg.In some embodiments, the anti-TREM2 antibody (e.g., "Ab-1") is administered to a human patient at a dose of about 50 mg / kg to about 100 mg / kg, about 50 mg / kg to about 90 mg / kg, about 50 mg / kg to about 80 mg / kg, about 50 mg / kg to about 70 mg / kg, or about 50 mg / kg to about 60 mg / kg. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient at a dose of about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 5 mg / kg, about 10 mg / kg, about 15 mg / kg, about 20 mg / kg, about 25 mg / kg, about 30 mg / kg, about 35 mg / kg, about 40 mg / kg, about 45 mg / kg, about 50 mg / kg, about 55 mg / kg, or about 60 mg / kg.

[0330] In some embodiments, the anti-TREM2 antibody is administered to a human patient once a day, 1, 2, 3, or 4 times a week, or 1, 2, 3, or 4 times a month. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient once a day. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient 1, 2, 3, or 4 times a week. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient 1, 2, 3, or 4 times a month. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient once a month, 1, 2, 3, or 4 times. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient once every 1 week, every 2 weeks, every 3 weeks, or every 4 weeks. In some embodiments, the anti-TREM2 antibody "Ab-1" is administered to a human patient once every 2 days, every 3 days, every 4 days, every 5 days, every 6 days, every 7 days, every 8 days, every 9 days, every 10 days, or every 14 days. In some embodiments, anti-TREM2 antibody "Ab-1" is administered to a human patient once a week.

[0331] In some embodiments, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1" at a concentration of up to about 300 mg / mL. In some embodiments, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1" at a concentration of up to about 250 mg / mL. In some embodiments, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1" at a concentration of up to about 200 mg / mL. In some embodiments, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1" at a concentration of up to about 150 mg / mL. In some embodiments, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1" at a concentration of about 300 mg / mL, about 250 mg / mL, about 200 mg / mL, about 180 mg / mL, about 170 mg / mL, about 160 mg / mL, about 150 mg / mL, about 140 mg / mL, about 130 mg / mL, about 120 mg / mL, about 110 mg / mL, or about 100 mg / mL. In some embodiments, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1" at a concentration of about 140 mg / mL. In some embodiments, the method of the present invention comprises administering a liquid formulation as described herein to a human patient. In some embodiments, the method of the present invention comprises administering a liquid formulation to a human patient, the liquid formulation comprising an anti-TREM2 antibody "Ab-1" at a concentration of about 140 mg / mL.

[0332] In some embodiments, the patient is between 18 and 55 years old (inclusive). In some embodiments, the patient is between 18 and 42 years old. In some embodiments, the patient is between 42 and 55 years old. In some embodiments, the patient is 42 years old or younger. In some embodiments, the patient is 42 years old or older.

[0333] In some embodiments, the patient is not a WOCBP (women of pregnancy). In some embodiments, the patient is a WOCBP who uses an effective contraceptive method during the course of treatment with an anti-TREM2 antibody and for at least 10 weeks after treatment.

[0334] In some embodiments, the patient is a non-smoker (or other nicotine / tobacco (including e-cigarette) user) as determined by medical history (no nicotine use in the past year). In some embodiments, the patient has a negative urine cotinine test shortly before or at the time of administration of the anti-TREM2 antibody "Ab-1".

[0335] In some embodiments, the patient has a body mass index (BMI) between 18.5 kg / m2 and 30.0 kg / m2 (inclusive). In some embodiments, the patient has a vital sign (systolic and diastolic blood pressure and pulse rate) assessment shortly before or at the time of receiving administration of anti-TREM2 antibody "Ab-1".

[0336] In some embodiments, the patient is of first generation Japanese descent. In some embodiments, the patient was born in Japan. In some embodiments, the patient's parents and grandparents are of Japanese descent and were born in Japan. In some embodiments, the patient has not had a significant change in lifestyle since leaving Japan. In some embodiments, the patient has lived outside of Japan for less than 10 years.

[0337] In some embodiments, the patient has no history or evidence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immune, or psychiatric disorders. In some embodiments, the patient has not received monoclonal antibody therapy within 120 days prior to receiving anti-TREM2 antibody "Ab-1". In some embodiments, the patient has no history of alcohol and / or illicit drug addiction within 2 years prior to receiving anti-TREM2 antibody "Ab-1".

[0338] In some embodiments, the patient does not test positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies, or human immunodeficiency virus (HIV) antibodies.

[0339] In some embodiments, the patient does not test positive for urine ethanol shortly before or at the time of administration of the anti-TREM2 antibody "Ab-1."

[0340] In some embodiments, the patient's urine contains drugs (e.g., cocaine, amphetamines, barbiturates, opioids, benzodiazepines) shortly before or at the time of administration of the anti-TREM2 antibody "Ab-1". Tests did not test positive for drugs (cannabinoids and cannabinoids) or cotinine.

[0341] In some embodiments, the patient is not a female patient who is breastfeeding shortly before or at the time of administration of the anti-TREM2 antibody "Ab-1".

[0342] In some embodiments, the patient is not a female patient who had a positive serum pregnancy test shortly before or at the time of receiving administration of anti-TREM2 antibody "Ab-1".

[0343] In some embodiments, the patient has not donated blood (>500 mL) or blood products within 2 months (56 days) prior to administration of anti-TREM2 antibody "Ab-1".

[0344] In some embodiments, the patient has not received any study drug within 30 days or 5 half-lives (whichever is longer) prior to receiving administration of anti-TREM2 antibody "Ab-1".

[0345] In some embodiments, the patient has no history of allergy to any of the therapeutic monoclonal antibodies, or to any of the excipients, or to pharmaceutical products with similar chemical structures.

[0346] In some embodiments, the patient does not test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription polymerase chain reaction (RT-PCR) shortly before or at the time of administration of anti-TREM2 antibody "Ab-1".

[0347] In some embodiments, the patient does not have any clinical signs and symptoms consistent with SARS-CoV-2 infection, e.g., fever, dry cough, dyspnea, sore throat, fatigue, or laboratory-confirmed acute SARS-CoV-2 infection, shortly before or at the time of administration of the anti-TREM2 antibody "Ab-1".

[0348] In some embodiments, the patient does not have a severe course of COVID-19 (COVID-19; extracorporeal membrane oxygenation, mechanical ventilation, intensive care unit hospitalization).

[0349] In some embodiments, the patient has not been recently (within 14 days prior to receiving administration of anti-TREM2 antibody "Ab-1") exposed to a person with COVID-19 symptoms or who tested positive for SARS-CoV-2.

[0350] In some embodiments, the patient has not received any COVID-19 treatment shortly before or at the time of administration of anti-TREM2 antibody "Ab-1".

[0351] In some embodiments, the patient has not received the final dose of the COVID-19 vaccine within 14 days prior to receiving administration of anti-TREM2 antibody "Ab-1" (i.e., they must have completed vaccination at least 14 days prior to inclusion).

[0352] In some embodiments, the patient receives genetic testing before the administration of anti-TREM2 antibody "Ab-1". In some embodiments, the patient does not have alanyl-tRNA synthetase 2 (AARS2) gene mutation, for example, as confirmed by genetic testing. In some embodiments, the patient has a colony stimulating factor 2 (CSF1R) gene mutation, for example, as confirmed by genetic testing. In some embodiments, the patient has a mutation in an exon (e.g., exon 1-21) in the CSF1R gene. In some embodiments, the patient has a mutation in an exon (e.g., exon 2-17 or 18-21) in the CSF1R gene. In some embodiments, the patient has signs or symptoms of ALSP. Exemplary signs or symptoms of ALSP include cognitive impairment, frontal lobe dysfunction, psychiatric symptoms, extrapyramidal symptoms, pyramidal symptoms, involuntary movements, gait disturbances, seizures, pathological reflexes, speech disorders, swallowing disorders, speech apraxia, sensory disturbances, autonomic symptoms, headaches, stroke, dementia, encephalitis, memory loss, depression, loss of executive function, bradykinesia, rigidity, and cerebellar symptoms.

[0353] In some embodiments, the patient exhibits a reduction in ALSP symptoms after administration of the anti-TREM2 antibody "Ab-1". In some embodiments, the patient exhibits a reduction in the severity of ALSP symptoms after administration of the anti-TREM2 antibody "Ab-1", for example, by about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, compared to the severity of the symptoms without administration of the anti-TREM2 antibody "Ab-1".

[0354] In some embodiments, the patient receives CSF collection by lumbar puncture shortly before, at, or after receiving the administration of anti-TREM2 antibody "Ab-1". In some embodiments, the patient receives CSF collection by lumbar puncture shortly before, at, or after receiving the first dose of anti-TREM2 antibody "Ab-1". In some embodiments, the patient receives CSF collection by lumbar puncture shortly before, at, or after receiving the second dose of anti-TREM2 antibody "Ab-1". In some embodiments, the patient receives CSF collection by lumbar puncture shortly before, at, or after receiving the third dose of anti-TREM2 antibody "Ab-1". In some embodiments, the patient does not receive CSF collection by lumbar puncture, wherein the patient is allergic to anesthetics or derivatives used during CSF collection or any drugs used to perform lumbar puncture in the area. In some embodiments, the patient does not receive CSF collection by lumbar puncture, wherein the patient has undergone CSF collection within 30 days before receiving the administration of anti-TREM2 antibody "Ab-1".

[0355] In some embodiments, the patient does not undergo CSF ​​collection by lumbar puncture, wherein the patient has a history of spinal deformity, major back surgery, clinically significant back pain, clinically significant abnormal X-rays, and / or injury.

[0356] In some embodiments, the patient does not undergo CSF ​​collection by lumbar puncture, wherein the patient has a persistent skin infection at the lumbar puncture injection site.

[0357] In some embodiments, the patient does not undergo CSF ​​collection by lumbar puncture, where the patient has clinically significant coagulation test values ​​outside of the normal reference range (prothrombin time / international normalized ratio, partial thromboplastin time) shortly before or at the time of administration of anti-TREM2 antibody "Ab-1".

[0358] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 60 minutes.

[0359] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 50 minutes.

[0360] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 45 minutes.

[0361] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 40 minutes.

[0362] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 35 minutes.

[0363] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 30 minutes.

[0364] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 25 minutes.

[0365] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 20 minutes.

[0366] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 15 minutes.

[0367] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 10 minutes.

[0368] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 60 mg / kg, about 50 mg / kg, about 40 mg / kg, about 30 mg / kg, about 20 mg / kg, about 10 mg / kg, about 5 mg / kg, about 3 mg / kg, about 2 mg / kg or about 1 mg / kg, wherein the duration of the intravenous infusion is about 5 minutes.

[0369] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 60 minutes.

[0370] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 50 minutes.

[0371] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 45 minutes.

[0372] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 40 minutes.

[0373] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 35 minutes.

[0374] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 30 minutes.

[0375] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 25 minutes.

[0376] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 20 minutes.

[0377] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 15 minutes.

[0378] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 10 minutes.

[0379] In some embodiments, the present invention provides a method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to the patient an anti-TREM2 antibody "Ab-1" by intravenous infusion at a dose of about 4.2 grams, about 3.5 grams, about 2.8 grams, about 2.1 grams, about 1.4 grams, about 700 mg, about 350 mg, about 210 mg, about 140 mg or about 70 mg, wherein the duration of the intravenous infusion is about 5 minutes.

[0380] In some embodiments, the present invention provides a method for reducing the level of sTREM2 in a subject, the method comprising administering an anti-TREM2 antibody VGL101 to the subject at a dose of about 1 mg / kg–100 mg / kg. In some embodiments, the level of sTREM2 is evaluated before administering VGL101. In some embodiments, the level of sTREM2 is the level in cerebrospinal fluid (CSF). In some embodiments, the level of sTREM2 is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%.

[0381] In some embodiments, the method comprises administering to the subject a dose of about 1 mg / kg–75 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg–50 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg–40 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient once a week the anti-TREM2 antibody.

[0382] In some embodiments, the present invention provides a method for reducing the level of sCSF1R in a subject, the method comprising administering an anti-TREM2 antibody VGL101 to the subject at a dose of about 1 mg / kg–100 mg / kg. In some embodiments, the level of sCSF1R is evaluated before administering VGL101. In some embodiments, the level of sCSF1R is the level in cerebrospinal fluid (CSF). In some embodiments, the level of sCSF1R is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%.

[0383] In some embodiments, the method comprises administering to the subject a dose of about 1 mg / kg–75 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg–50 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg–40 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody. In some embodiments, the method comprises administering to the human patient once a week the anti-TREM2 antibody.

[0384] In some embodiments, the present invention provides a method of binding or stimulating TREM2 in a subject, the method comprising administering to the subject an anti-TREM2 antibody VGL101 at a dose of about 1 mg / kg–100 mg / kg. In some embodiments, the method comprises administering to the subject an anti-TREM2 antibody at a dose of about 1 mg / kg–75 mg / kg. In some embodiments, the method comprises administering to the human patient an anti-TREM2 antibody at a dose of about 1 mg / kg–60 mg / kg. In some embodiments, the method comprises administering to the human patient an anti-TREM2 antibody at a dose of about 1 mg / kg–50 mg / kg. In some embodiments, the method comprises administering to the human patient an anti-TREM2 antibody at a dose of about 1 mg / kg–40 mg / kg. In some embodiments, the method comprises administering to the human patient an anti-TREM2 antibody at a dose of about 1 mg / kg–30 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg. In some embodiments, the method comprises administering the anti-TREM2 antibody to the human patient once a week.

[0385] Liquid preparations

[0386] In some embodiments, the present invention provides a liquid formulation comprising an anti-TREM2 antibody "Ab-1" and a pharmaceutically acceptable excipient (e.g., a buffer) and / or a carrier (e.g., water). The amount of the anti-TREM2 antibody "Ab-1" in the liquid formulation of the present invention enables the antibody to effectively and measurably inhibit TREM2 or a mutant thereof in a patient. In certain embodiments, the liquid formulation of the present invention is formulated for administration to a patient in need of such a composition. In some embodiments, the composition of the present invention is formulated for parenteral (e.g., intravenous) administration to a patient.

[0387] In some embodiments, the liquid formulations of the present invention comprise an anti-TREM2 antibody "Ab-1" at a concentration of about 50 mg / mL to about 250 mg / mL. In some embodiments, the liquid formulations of the present invention comprise an anti-TREM2 antibody "Ab-1" at a concentration of about 70 mg / mL to about 230 mg / mL, about 90 mg / mL to about 210 mg / mL, about 100 mg / mL to about 200 mg / mL, about 120 mg / mL to about 180 mg / mL, about 120 mg / mL to about 160 mg / mL, or about 130 mg / mL to about 150 mg / mL. In some embodiments, the liquid formulation of the present invention comprises an anti-TREM2 antibody "Ab-1" at a concentration of about 80 mg / mL, about 90 mg / mL, about 100 mg / mL, about 110 mg / mL, about 120 mg / mL, about 130 mg / mL, about 140 mg / mL, about 150 mg / mL, about 160 mg / mL, about 170 mg / mL, about 180 mg / mL, about 190 mg / mL, or about 200 mg / mL. In some embodiments, the liquid formulation of the present invention comprises an anti-TREM2 antibody "Ab-1" at a concentration of about 135 mg / mL, about 136 mg / mL, about 137 mg / mL, about 138 mg / mL, about 139 mg / mL, about 140 mg / mL, about 141 mg / mL, about 142 mg / mL, about 143 mg / mL, about 144 mg / mL, or about 145 mg / mL.

[0388] In some embodiments, liquid preparation of the present invention comprises sodium acetate.In some embodiments, liquid preparation of the present invention comprises sodium acetate for concentration of about 5mM to about 25mM.In some embodiments, liquid preparation of the present invention comprises sodium acetate for concentration of about 6mM to about 24mM, about 7mM to about 23mM, about 8mM to about 22mM, about 9mM to about 21mM, about 10mM to about 20mM, about 11mM to about 19mM, about 12mM to about 18mM, about 13mM to about 17mM or about 14mM to about 16mM.In some embodiments, liquid preparation of the present invention comprises sodium acetate for concentration of about 10mM, about 11mM, about 12mM, about 13mM, about 14mM, about 15mM, about 16mM, about 17mM, about 18mM, about 19mM or about 20mM. In some embodiments, the liquid formulation of the present invention comprises sodium acetate at a concentration of about 14.5 mM, about 14.6 mM, about 14.7 mM, about 14.8 mM, about 14.9 mM, about 15 mM, about 15.1 mM, about 15.2 mM, about 15.3 mM, about 15.4 mM, or about 15.5 mM.

[0389] In some embodiments, the liquid preparation of the present invention comprises sucrose. In some embodiments, the liquid preparation of the present invention comprises a concentration of about 4% to about 14% (w / v) sucrose of the total liquid preparation volume. In some embodiments, the liquid preparation of the present invention comprises a concentration of about 5% to about 13%, about 6% to about 12%, about 7% to about 11% or about 8% to about 10% (w / v) sucrose of the total liquid preparation volume. In some embodiments, the liquid preparation of the present invention comprises a concentration of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11% or about 12% (w / v) sucrose of the total liquid preparation volume. In some embodiments, the liquid preparation of the present invention comprises a concentration of about 8.5%, about 8.6%, about 8.7%, about 8.8%, about 8.9%, about 9%, about 9%, about 9.1%, about 9.2%, about 9.3%, about 9.4% or about 9.5% (w / v) sucrose of the total liquid preparation volume.

[0390] In some embodiments, the liquid formulations of the present invention comprise polysorbate 80. In some embodiments, the liquid formulations of the present invention comprise polysorbate 80 at a concentration of about 0.005% to about 0.015% (w / v) of the total liquid formulation volume. In some embodiments, the liquid formulations of the present invention comprise polysorbate 80 at a concentration of about 0.006% to about 0.014%, about 0.007% to about 0.013%, about 0.008% to about 0.012%, or about 0.009% to about 0.011% (w / v) of the total liquid formulation volume. In some embodiments, the liquid formulations of the present invention comprise polysorbate 80 at a concentration of about 0.005%, about 0.006%, about 0.007%, about 0.008%, about 0.009%, about 0.01%, about 0.011%, about 0.012%, about 0.013%, about 0.014%, or about 0.015% (w / v) of the total liquid formulation volume.

[0391] In some embodiments, the pH of the liquid formulation of the present invention is about 4.4 to about 6.0. In some embodiments, the pH of the liquid formulation of the present invention is about 4.4 to about 6.0, about 4.5 to about 5.9, about 4.6 to about 5.8, about 4.7 to about 5.7, about 4.8 to about 5.6, about 4.9 to about 5.5, about 5.0 to about 5.4, or about 5.1 to about 5.3. In some embodiments, the liquid formulation of the present invention is about pH 4.8, about pH 4.9, about pH 5.0, about pH 5.1, about pH 5.2, about pH 5.3, about pH 5.4, about pH 5.5, or about pH 5.6. In some embodiments, the liquid formulations of the invention are about pH 5.16, about pH 5.17, about pH 5.18, about pH 5.19, about pH 5.20, about pH 5.21, about pH 5.22, about pH 5.23, or about pH 5.24.

[0392] In certain embodiments, the liquid formulation of the present invention comprises an anti-TREM2 antibody "Ab-1" at a concentration of about 140 mg / mL. In some embodiments, the liquid formulation of the present invention comprises sodium acetate at a concentration of about 15 mM. In some embodiments, the liquid formulation of the present invention comprises sucrose at a concentration of about 9% (w / v) of the total liquid formulation volume. In some embodiments, the liquid formulation of the present invention comprises polysorbate 80 at a concentration of about 0.01% (w / v) of the total liquid formulation volume. In some embodiments, the liquid formulation of the present invention is about pH 5.2.

[0393] In certain embodiments, the present invention provides a liquid formulation comprising:

[0394] an anti-TREM2 antibody "Ab-1" at a concentration of about 140 mg / mL;

[0395] Sodium acetate at a concentration of about 15 mM;

[0396] Sucrose at a concentration of about 9% (w / v) of the total liquid formulation volume;

[0397] Polysorbate 80 at a concentration of about 0.01% (w / v) of the total liquid formulation volume; and

[0398] pH of about 5.2.

[0399] The liquid preparations of the present invention can be administered parenterally in the form of liquid preparations by injection, infusion or implantation (intravenous, intramuscular, subcutaneous, etc.), or by suitable delivery devices or implants containing conventional, non-toxic pharmaceutically acceptable carriers and adjuvants.

[0400] If necessary, the liquid preparation may also include a solubilizing agent. The components of the preparation may exist alone, or may be mixed together in a unit dosage form, for example, in a sealed container (such as an ampoule or a sachet) in the form of a dry lyophilized powder (which may be reconstituted with a carrier (such as saline) before use) or a concentrated solution, and the amount of the active agent is indicated. If the composition is administered by infusion, an infusion bottle or an infusion bag containing sterile pharmaceutical grade water or saline may be used to distribute the composition. When the preparation is administered by injection, an ampoule of sterile water or saline may be provided so that the ingredients may be mixed before injection.

[0401] The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, one or more polyols (e.g., glycerol, propylene glycol and liquid polyethylene glycol), oils (such as vegetable oils (e.g., peanut oil, corn oil, sesame oil, etc.)) and combinations thereof. Appropriate fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size of the dispersion, and / or by using a surfactant. In many cases, it will be preferred to include an isotonic agent, for example, a sugar or sodium chloride. In a preferred aspect, water is added to the liquid formulation of the present invention.

[0402] Solutions and dispersions of the active compound can be prepared as the free acid or free base or a pharmacologically acceptable salt thereof in water or another solvent or dispersion medium suitably mixed with one or more pharmaceutically acceptable excipients including, but not limited to, buffers, surfactants, dispersants, emulsifiers, viscosity modifiers, and combinations thereof.

[0403] Suitable surfactants can be anionic, cationic, zwitterionic or nonionic surfactants. Suitable anionic surfactants include, but are not limited to, anionic surfactants containing carboxylate, sulfonate and sulfate ions. Examples of anionic surfactants include sodium salts, potassium salts, ammonium salts of long-chain alkyl sulfonic acids and alkyl aryl sulfonic acids, such as sodium dodecylbenzene sulfonate; sodium dialkyl sulfosuccinates, such as sodium dodecylbenzene sulfonate; sodium dialkyl sulfosuccinates, such as bis-(2-ethylsulfinyl)-sodium sulfosuccinate; and alkyl sulfates, such as sodium lauryl sulfate. Cationic surfactants include, but are not limited to, quaternary ammonium compounds, such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethyl benzyl ammonium chloride, polyoxyethylene and coconut amine. Examples of the nonionic surfactant include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbate, polyoxyethylene octylphenyl ether, PEG-1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, 401, stearyl monoisopropanolamide and polyoxyethylene hydrogenated tallow amide. Examples of amphoteric surfactants include sodium N-dodecyl-β-alanine, sodium N-dodecyl β-iminodipropionate, myristoylamphoacetate, lauryl betaine and lauryl sulfobetaine. The preparation may contain a preservative to prevent microbial growth. Suitable preservatives include, but are not limited to, parabens, chlorobutanol, phenol, sorbic acid and thimerosal. The preparation may also contain an antioxidant to prevent degradation of the active agent.

[0404] Water-soluble polymers are often used in formulations for parenteral administration. Suitable water-soluble polymers include, but are not limited to, polyvinyl pyrrolidone, dextran, carboxymethyl cellulose, and polyethylene glycol.

[0405] Sterile injection solution can be prepared in the following manner: the required amount of active compound and one or more excipients listed above are mixed in a suitable solvent or dispersion medium, and then filtered and sterilized as needed. Generally speaking, dispersions are prepared in the following manner: various sterilized active ingredients are mixed in a sterile vehicle, and the sterile vehicle contains a basic dispersion medium and other required ingredients listed above. For the sterile powder for the preparation of sterile injection solution, the preferred preparation method is vacuum drying and freeze drying technology, which produces a powder of active ingredient plus any desired additional ingredients from the sterile filtered solution before. The preparation method of the powder can make the particles porous in nature, which can increase the dissolution of the particles. The method for preparing porous particles is well known in the art.

[0406] In some embodiments, the liquid preparation of the present invention is mixed with an intravenous infusion vehicle. In some embodiments, the liquid preparation is mixed with an injection medium (such as normal saline (0.9% sodium chloride), 5% glucose (D5W) and lactated Ringer's injection). In some embodiments, the present invention provides a liquid pharmaceutical composition, which is prepared by mixing the liquid preparation of the present invention with water and then diluting it with saline or 5% glucose. In some embodiments, the liquid pharmaceutical composition is diluted into a saline or 5% glucose intravenous bag for intravenous administration. In some embodiments, the liquid pharmaceutical composition in the saline or 5% glucose intravenous bag can be stored at room temperature (about 20°C-25°C) for up to about 4 hours before intravenous administration. In some embodiments, the liquid pharmaceutical composition in the saline or 5% glucose intravenous bag can be stored under refrigeration (about 2°C-8°C) for up to about 20 hours before intravenous administration. In some embodiments, liquid pharmaceutical compositions in saline or 5% dextrose IV bags may be stored under refrigeration (about 2°C-8°C) for up to about 20 hours prior to intravenous administration and then stored at room temperature (about 20°C-25°C) for up to about 4 hours.

[0407] It should also be understood that the specific dosage and treatment regimen for any particular patient will depend on a variety of factors, including the activity of the specific compound employed, age, weight, general health, sex, diet, time of administration, rate of excretion, drug combination and the judgment of the treating physician as well as the severity of the particular disease being treated.

[0408] List of implementation plans

[0409] The disclosure herein is further provided as a non-limiting list of numbered embodiments.

[0410] 1. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering an anti-TREM2 antibody at a dose of about 1 mg / kg–100 mg / kg to a patient in need thereof.

[0411] 2. A method as described in embodiment 1, wherein the anti-TREM2 antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region comprising CDRL1 having an amino acid sequence according to SEQ ID NO:2; CDRL2 having an amino acid sequence according to SEQ ID NO:3; and CDRL3 having an amino acid sequence according to SEQ ID NO:4, and the heavy chain variable region comprises CDRH1 having an amino acid sequence according to SEQ ID NO:6; CDRH2 having an amino acid sequence according to SEQ ID NO:7; and CDRH3 having an amino acid sequence according to SEQ ID NO:8.

[0412] 3. A method as described in any of the preceding embodiments, wherein the anti-TREM2 antibody comprises a light chain variable region and a heavy chain variable region, the light chain variable region having an amino acid sequence according to SEQ ID NO:1, and the heavy chain variable region having an amino acid sequence according to SEQ ID NO:5.

[0413] 4. A method as described in any of the preceding embodiments, wherein the anti-TREM2 antibody is IgG, optionally IgG1.

[0414] 5. A method as described in any of the preceding embodiments, wherein the anti-TREM2 antibody comprises a κ light chain constant region.

[0415] 6. A method as described in any of the preceding embodiments, wherein the anti-TREM2 antibody is IgG1, comprising a variant constant region having one or more mutations selected from the following: R292C, N297G, V302C, D356E or L358M, according to EU numbering.

[0416] 7. A method as described in any of the preceding embodiments, wherein the anti-TREM2 antibody is the anti-TREM2 antibody VGL101, and the anti-TREM2 antibody VGL101 comprises a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQID NO:10.

[0417] 8. The method of any one of embodiments 1 to 7, comprising administering to the human patient a dose of about 1 mg / kg–75 mg / kg of the anti-TREM2 antibody.

[0418] 9. The method of any one of embodiments 1 to 7, comprising administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0419] 10. The method of any one of embodiments 1 to 7, comprising administering to the human patient a dose of about 1 mg / kg–50 mg / kg of the anti-TREM2 antibody.

[0420] 11. The method of any one of embodiments 1 to 7, comprising administering to the human patient a dose of about 1 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0421] 12. The method of any one of embodiments 1 to 7, comprising administering to the human patient a dose of about 10 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0422] 13. The method of any one of embodiments 1 to 7, comprising administering to the human patient a dose of about 20 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0423] 14. The method of any one of embodiments 1 to 7, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody.

[0424] 15. The method of any one of embodiments 1 to 14, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a week.

[0425] 16. The method of any one of embodiments 1 to 14, wherein the method comprises administering the anti-TREM2 antibody to the human patient once every two weeks.

[0426] 17. The method of any one of embodiments 1 to 14, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a month.

[0427] 18. The method of any one of embodiments 1 to 17, wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion.

[0428] 19. A method as described in embodiment 18, wherein the intravenous infusion of the anti-TREM2 antibody is between 1 and 4 hours, for example, about 4 hours, 3 hours, 2 hours, about 60 minutes, about 45 minutes, about 30 minutes.

[0429] 20. A liquid formulation comprising an anti-TREM2 antibody VGL101 at a concentration of approximately 140 mg / mL and a pharmaceutically acceptable excipient and / or carrier.

[0430] 21. The liquid formulation of embodiment 20, further comprising sodium acetate at a concentration of about 15 mM.

[0431] 22. The liquid formulation of embodiment 20 or embodiment 21, further comprising sucrose at a concentration of about 9% (w / v) of the total liquid formulation volume.

[0432] 23. The liquid formulation of any one of embodiments 20 to 22, further comprising polysorbate 80 at a concentration of about 0.01% (w / v) of the total liquid formulation volume.

[0433] 24. The liquid formulation of any one of embodiments 20 to 23, wherein the liquid formulation is about pH 5.2.

[0434] 25. A liquid formulation at about pH 5.2, comprising:

[0435] the anti-TREM2 antibody VGL101 at a concentration of about 140 mg / mL;

[0436] Sodium acetate at a concentration of about 15 mM;

[0437] Sucrose at a concentration of about 9% (w / v) by volume of the total liquid formulation; and

[0438] Polysorbate 80 at a concentration of about 0.01% (w / v) of the total liquid formulation volume.

[0439] 26. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to a patient in need thereof a therapeutically effective amount of the liquid formulation of any one of embodiments 20 to 25.

[0440] 27. A method as described in embodiment 26, wherein the method comprises administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody VGL101.

[0441] 28. A method as described in embodiment 26, wherein the method comprises administering a dose of about 20 mg / kg–40 mg / kg of the anti-TREM2 antibody VGL101 to the human patient.

[0442] 29. A method as described in embodiment 26, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg or about 40 mg / kg of the anti-TREM2 antibody VGL101.

[0443] 30. A method as described in any one of embodiments 26 to 29, wherein the method comprises administering the anti-TREM2 antibody VGL101 to the human patient once a week.

[0444] 31. The method of any one of embodiments 26 to 29, wherein the method comprises administering the anti-TREM2 antibody to the human patient once every two weeks.

[0445] 32. The method of any one of embodiments 26 to 29, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a month.

[0446] 33. A method as described in any one of embodiments 26 to 32, wherein the method comprises administering the anti-TREM2 antibody VGL101 to the human patient by intravenous infusion.

[0447] 34. A method as described in embodiment 33, wherein the intravenous infusion of anti-TREM2 antibody VGL101 is about 60 minutes.

[0448] 35. A method for reducing the level of sTREM2 in a subject, the method comprising administering the anti-TREM2 antibody VGL101 to the subject at a dose of about 1 mg / kg–100 mg / kg.

[0449] 36. A method as described in embodiment 35, wherein the level of sTREM2 is evaluated before administering VGL101.

[0450] 37. A method as described in embodiment 35 or embodiment 36, wherein the level of sTREM2 is the level in cerebrospinal fluid (CSF).

[0451] 38. The method of embodiment 35 or embodiment 36, wherein the level of sTREM2 is the level in serum.

[0452] 39. The method of any one of embodiments 35 to 38, wherein the level of sTREM2 is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%.

[0453] 40. The method of any one of embodiments 35 to 39, wherein the method comprises administering to the subject a dose of about 1 mg / kg–75 mg / kg of the anti-TREM2 antibody.

[0454] 41. The method of any one of embodiments 35 to 39, comprising administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0455] 42. The method of any one of embodiments 35 to 39, comprising administering to the human patient a dose of about 1 mg / kg–50 mg / kg of the anti-TREM2 antibody.

[0456] 43. The method of any one of embodiments 35 to 39, comprising administering to the human patient a dose of about 1 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0457] 44. The method of any one of embodiments 35 to 39, comprising administering to the human patient a dose of about 10 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0458] 45. The method of any one of embodiments 35 to 39, comprising administering to the human patient a dose of about 20 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0459] 46. ​​The method of any one of embodiments 35 to 39, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody.

[0460] 47. The method of any one of embodiments 35 to 46, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a week.

[0461] 48. The method of any one of embodiments 35 to 46, wherein the method comprises administering the anti-TREM2 antibody to the human patient once every two weeks.

[0462] 49. The method of any one of embodiments 35 to 46, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a month.

[0463] 50. The method of any one of embodiments 35 to 49, wherein the method comprises administering the anti-TREM2 antibody VGL101 to the human patient by intravenous infusion.

[0464] 51. A method as described in embodiment 50, wherein the intravenous infusion of anti-TREM2 antibody VGL101 is about 60 minutes.

[0465] 52. A method for reducing the level of sCSF1R in a subject, the method comprising administering anti-TREM2 antibody VGL101 to the subject at a dose of about 1 mg / kg–100 mg / kg.

[0466] 53. The method of embodiment 52, wherein the level of sCSF1R is assessed prior to administration of VGL101.

[0467] 54. The method of embodiment 52 or embodiment 53, wherein the level of sCSF1R is the level in cerebrospinal fluid (CSF).

[0468] 55. The method of embodiment 52 or embodiment 53, wherein the level of sCSF1R is the level in serum.

[0469] 56. The method of any one of embodiments 52 to 55, wherein the level of sCSF1R is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%.

[0470] 57. The method of any one of embodiments 52 to 56, wherein the method comprises administering to the subject a dose of about 1 mg / kg–75 mg / kg of the anti-TREM2 antibody.

[0471] 58. The method of any one of embodiments 52 to 56, comprising administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0472] 59. The method of any one of embodiments 52 to 56, comprising administering to the human patient a dose of about 1 mg / kg–50 mg / kg of the anti-TREM2 antibody.

[0473] 60. The method of any one of embodiments 52 to 56, comprising administering to the human patient a dose of about 1 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0474] 61. The method of any one of embodiments 52 to 56, comprising administering to the human patient a dose of about 10 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0475] 62. The method of any one of embodiments 52 to 56, comprising administering to the human patient a dose of about 20 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0476] 63. The method of any one of embodiments 52 to 56, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody.

[0477] 64. The method of any one of embodiments 52 to 63, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a week.

[0478] 65. The method of any one of embodiments 52 to 63, wherein the method comprises administering the anti-TREM2 antibody to the human patient once every two weeks.

[0479] 66. The method of any one of embodiments 52 to 63, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a month.

[0480] 67. The method of any one of embodiments 52 to 66, wherein the method comprises administering the anti-TREM2 antibody VGL101 to the human patient by intravenous infusion.

[0481] 68. A method as described in embodiment 67, wherein the intravenous infusion of anti-TREM2 antibody VGL101 is about 60 minutes.

[0482] 69. A method for binding or stimulating TREM2 in a subject, the method comprising administering to the subject the anti-TREM2 antibody VGL101 at a dose of about 1 mg / kg–100 mg / kg.

[0483] 70. The method of embodiment 69, wherein the method comprises administering to the subject a dose of approximately 1 mg / kg–75 mg / kg of the anti-TREM2 antibody.

[0484] 71. The method of embodiment 69, wherein the method comprises administering to the human patient a dose of approximately 1 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0485] 72. The method of embodiment 69, wherein the method comprises administering to the human patient a dose of approximately 1 mg / kg–50 mg / kg of the anti-TREM2 antibody.

[0486] 73. The method of embodiment 69, wherein the method comprises administering to the human patient a dose of approximately 1 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0487] 74. The method of embodiment 69, wherein the method comprises administering to the human patient a dose of approximately 10 mg / kg–60 mg / kg of the anti-TREM2 antibody.

[0488] 75. The method of embodiment 69, wherein the method comprises administering to the human patient a dose of approximately 20 mg / kg–40 mg / kg of the anti-TREM2 antibody.

[0489] 76. The method of embodiment 69, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody.

[0490] 77. The method of any one of embodiments 69 to 76, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a week.

[0491] 78. The method of any one of embodiments 69 to 76, wherein the method comprises administering the anti-TREM2 antibody to the human patient once every two weeks.

[0492] 79. The method of any one of embodiments 69 to 76, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a month.

[0493] 80. The method of any one of embodiments 69 to 79, wherein the method comprises administering the anti-TREM2 antibody VGL101 to the human patient by intravenous infusion.

[0494] 81. The method of embodiment 80, wherein the intravenous infusion of anti-TREM2 antibody VGL101 is about 60 minutes.

[0495] 82. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering an anti-TREM2 antibody at a dose of about 20 mg / kg to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0496] 83. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering an anti-TREM2 antibody at a dose of about 30 mg / kg to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0497] 84. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering an anti-TREM2 antibody at a dose of about 40 mg / kg to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0498] 85. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering an anti-TREM2 antibody at a dose of about 50 mg / kg to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0499] 86. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering a dose of about 60 mg / kg of an anti-TREM2 antibody to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0500] 87. A method for reducing the level of sCSF1R in a subject, the method comprising administering an anti-TREM2 antibody at a dose of about 20 mg / kg to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, the anti-TREM2 antibody VGL101 comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0501] 88. A method for reducing the level of sCSF1R in a subject, the method comprising administering an anti-TREM2 antibody at a dose of about 30 mg / kg to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, the anti-TREM2 antibody VGL101 comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0502] 89. A method for reducing the level of sCSF1R in a subject, the method comprising administering a dose of about 40 mg / kg of an anti-TREM2 antibody to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, the anti-TREM2 antibody VGL101 comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0503] 90. A method for reducing the level of sCSF1R in a subject, the method comprising administering an anti-TREM2 antibody at a dose of about 50 mg / kg to a patient in need thereof, wherein the anti-TREM2 antibody is anti-TREM2 antibody VGL101, the anti-TREM2 antibody VGL101 comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0504] 91. A method for reducing the level of sCSF1R in a subject, wherein the anti-TREM2 antibody is the anti-TREM2 antibody VGL101, the anti-TREM2 antibody VGL101 comprising a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:10, and wherein the method comprises administering the anti-TREM2 antibody to the human patient by intravenous infusion once every 28 days.

[0505] example

[0506] Anti-TREM2 antibodies, such as "Ab-1", can be prepared by any method known to a person of ordinary skill in the art, for example, as described in WO2018 / 195506A1, the contents of which are incorporated herein by reference in their entirety.

[0507] Abbreviations

[0508] λz: terminal elimination rate constant

[0509] AE: adverse event

[0510] AL:P alkaline phosphatase

[0511] ALSP: axonal spheroids and pigmented glial cells

[0512] ALT: Alanine aminotransferase

[0513] APOE: Apolipoprotein E

[0514] AST: Aspartate aminotransferase

[0515] AUC0-inf: Area under the serum or CSF concentration-time curve from before drug administration (time 0) to infinite time (AUClast + Clast / λz)

[0516] AUC0-last: The area under the serum or CSF concentration-time curve from before dosing (time 0) to the time of the last quantifiable concentration (tlast)

[0517] AUCtau: area under the serum or CSF concentration-time curve during the dosing interval

[0518] AUMC: Area under the first moment curve

[0519] BMI: Body Mass Index

[0520] CCL2: Chemokine ligand 2

[0521] CFR: Code of Federal Regulations

[0522] CL: systemic clearance

[0523] Cmax: maximum serum / cerebrospinal fluid concentration

[0524] CNS: Central nervous system

[0525] COVID-19: Coronavirus disease 2019

[0526] CSF: cerebrospinal fluid

[0527] CSF1R: colony stimulating factor-1 receptor

[0528] CTR: Clinical Trial Report

[0529] C-SSRS: Columbia-Suicide Severity Rating Scale

[0530] Ctrough: concentration before dose administration

[0531] CV%: Coefficient of variation%

[0532] ECG: electrocardiogram

[0533] eCRF: Electronic Case Report Form

[0534] ER: Emergency Room

[0535] EOS: Research concluded

[0536] FDA: U.S. Food and Drug Administration

[0537] FIH: First in Human

[0538] FSH: Follicle Stimulating Hormone

[0539] GCP: Good Clinical Practice

[0540] GLP: Good Laboratory Practice

[0541] HBsAg: Hepatitis B surface antigen

[0542] HIV: Human Immunodeficiency Virus

[0543] HSCT: Hematopoietic stem cell transplantation

[0544] IB: Investigator's Handbook

[0545] ICF: Informed Consent

[0546] ICH: International Council for Harmonization

[0547] IL: interleukin

[0548] IMP: Investigational Medicinal Product

[0549] IND: Investigational New Drug

[0550] IP-10: 10 kDa interferon-γ-induced protein

[0551] IRB: Institutional Review Board

[0552] IV: Intravenous

[0553] MAD: multiple ascending dose

[0554] MCP-1: Monocyte chemoattractant protein-1

[0555] MDM: monocyte-derived macrophages

[0556] MedDRA: Medical Dictionary for Regulatory Activities

[0557] MRT: Mean dwell time

[0558] N: number of observations

[0559] NfL: neurofilament light chain

[0560] NHP: Non-human primate

[0561] NOAEL: No Observed Adverse Effect Level

[0562] PCR: polymerase chain reaction

[0563] PD: Pharmacodynamics

[0564] PI: Principal Investigator

[0565] PK: Pharmacokinetics

[0566] PT: Preferred term

[0567] q7d: once every 7 days

[0568] RR: Respiration rate

[0569] RoAUC0-tau: cumulative rate, AUC0-tau (last dose) divided by AUC0-tau (first dose)

[0570] RoCmax: cumulative ratio, Cmax of the last dose divided by Cmax on day 1.

[0571] RT-PCR: reverse transcription polymerase chain reaction

[0572] SAD: Single ascending dose

[0573] SAE: Serious adverse event

[0574] SAP: Statistical Analysis Program

[0575] SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

[0576] SD: Standard deviation

[0577] SID: Subject Identification

[0578] SM: Safety Margin

[0579] SOP: Standard Operating Procedure

[0580] SRC: Safety Review Committee

[0581] t 1 / 2: Terminal elimination half-life

[0582] Tmax: time of maximum serum / cerebrospinal fluid concentration

[0583] TREM2: triggering receptor expressed on myeloid cells 2

[0584] Vss: Steady-state distribution volume

[0585] Vz: distribution volume

[0586] WHO: World Health Organization

[0587] WOCBP: Women of pregnancy

[0588] Example 1. A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Intravenous Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the Anti-TREM2 Antibody “Ab-1” in Healthy Adults

[0589] 1. Objectives:

[0590] main:

[0591] Determine the safety and tolerability of single ascending and multiple ascending intravenous (IV) doses of the anti-TREM2 antibody “Ab-1” in healthy adult participants

[0592] secondary:

[0593] Characterize the single-dose and multiple-dose serum pharmacokinetics (PK) of intravenous anti-TREM2 antibody “Ab-1” in healthy adult participants

[0594] To evaluate the immunogenicity of single and multiple ascending intravenous doses of the anti-TREM2 antibody “Ab-1” in healthy adult participants

[0595] To evaluate the pharmacokinetics of the anti-TREM2 antibody “Ab-1” in cerebrospinal fluid (CSF) following single and multiple doses.

[0596] Exploratory:

[0597] Study pharmacodynamic (PD) biomarkers in serum and CSF to provide reference for the mechanism of action of the anti-TREM2 antibody "Ab-1" to be developed in the future

[0598] To investigate whether apolipoprotein E4 genotypes produce differential responses to the anti-TREM2 antibody “Ab-1”

[0599] Determine the safety and tolerability of single ascending intravenous doses of the anti-TREM2 antibody “Ab-1” in healthy Japanese adult participants

[0600] To characterize the single-dose pharmacokinetics of intravenous anti-TREM2 antibody “Ab-1” in healthy Japanese adult participants.

[0601] 2. Design:

[0602] This is a 2-part, first-in-human (FIH), Phase 1, randomized, single-center, double-blind (sponsor open), placebo-controlled, dose-escalation study evaluating the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of the anti-TREM2 antibody "Ab-1" administered intravenously to healthy adult participants.

[0603] Part A is a single ascending dose (SAD) study conducted in approximately 40 healthy adult participants. The study includes 5 cohorts (cohort 1A to cohort 5A). Part A evaluated a single dose of the anti-TREM2 antibody "Ab-1" administered as an intravenous infusion over 60 minutes at 5 different dose levels. The doses for cohorts 1A to 5A are 1 mg / kg, 3 mg / kg, 10 mg / kg, 20 mg / kg, and 40 mg / kg; the dose can be adjusted based on ongoing evaluation. Two optional additional cohorts (cohort 6A and cohort 7A) can be included, where the dose for cohort 6A is below the maximum allowed exposure of 60 mg / kg, and cohort 7A is a Japanese cohort. The dose during this part of the study is determined by the sponsor as the study progresses. Safety, pharmacokinetic, and pharmacodynamic data were evaluated.

[0604] (a) Sentinel dosing is planned for all SAD cohorts. The first 2 participants in each cohort will be randomized and administered study treatment so that 1 participant receives the anti-TREM2 antibody "Ab-1" and the other participant receives a placebo. The remaining 6 healthy adult participants are randomized at a ratio of 5:1 (anti-TREM2 antibody "Ab-1": placebo). The remaining 6 participants in the cohort will not be administered study treatment until the investigator reviews the safety data for up to 48 hours after dosing of the first 2 participants in each cohort. The cohorts are tested sequentially in a dose-escalating manner, and available pharmacokinetic / pharmacodynamic data and at least 7 days of safety data are reviewed before escalating to the next cohort. Each cohort should have at least 6 participants complete the last dose for at least 7 days to trigger a safety review of dose escalation; participants who stop or withdraw midway will be replaced at the sponsor's discretion.

[0605] (b) (Optional) For 36-hour continuous CSF sample collection, participants in Cohorts 2A to 5A and optionally Cohort 6A will undergo indwelling catheter implantation in the lumbar subarachnoid space. The time points for CSF collection correspond to the pharmacokinetic time points.

[0606] (c) The total study duration for each participant was approximately 113 days, including up to 28 days of screening, inclusion (Day -2) and baseline assessment times, a 1-day treatment period, and an 84-day follow-up period after the Day 1 visit until the end-of-study (EOS) visit.

[0607] Part B is a multiple ascending dose (MAD) study conducted in approximately 16 healthy adult participants. Part B of the study is planned to include two cohorts (cohort 1B and cohort 2B). Cohorts 1B and 2B will randomly assign 8 healthy adult participants to receive three intravenous administrations of anti-TREM2 antibody "Ab-1" or placebo at a ratio of 6:2 during the study. The dose of anti-TREM2 antibody "Ab-1" or placebo in Part B is administered once every 28 days, assuming that a total of 3 infusions are required to reach steady state. The optional cohort 3B can be included at the same time as cohort 2B, including 6 participants, all of whom receive intravenous administration of anti-TREM2 antibody "Ab-1" (equal to or lower than the dose selected for cohort 2B). Participants in cohort 3B receive extended CSF collection by lumbar puncture on day 1 (before dosing), day 58 / 59, day 64 (inclusion on day 63), day 85 (inclusion on day 84), and day 103 (inclusion on day 102). There is an option to include an additional cohort (Cohort 4B) in which 8 participants receive intravenous administration (60 mg / kg) of anti-TREM2 antibody "Ab-1" or placebo in a 6:2 ratio. Dosing during this part of the study is determined as the study progresses. Safety, pharmacokinetic, and pharmacodynamic data will be assessed.

[0608] (a) Sentinel dosing will not be used in Part B of the study. The expected exposure levels in the MAD have been previously shown to be safe and well tolerated in healthy adult participants as a single dose in Part A. Cohorts are tested sequentially in a dose-escalation manner, and available pharmacokinetic / pharmacodynamic data and at least 7 days of safety data are reviewed before escalating to the next cohort. Each cohort should have at least 6 participants complete at least 7 days after the last dose to trigger a safety review of dose escalation; participants who discontinue or withdraw will be replaced at the discretion of the sponsor.

[0609] (b) For CSF sample collection, participants in all cohorts underwent lumbar puncture on Day 1 (pre-dose CSF collection) and Day 58 / 59 (between 24 hours and 48 hours after the third dose). Participants in Cohort 3B underwent extended CSF collection via lumbar puncture,

[0610] As described above.

[0611] (c) The total study duration for each participant was approximately 169 days, including a 28-day screening, inclusion (Day -2) and baseline assessment period, a 57-day treatment period, and an 84-day follow-up period after the last dose visit (Day 57) until the EOS visit.

[0612] Number of participants

[0613] Approximately 54 to 96 healthy adult participants were included.

[0614] Part A: 40 to 56 healthy adult participants

[0615] Approximately 40 healthy adult participants were enrolled in five dosing cohorts. An additional 16 healthy adult participants were enrolled in two additional optional cohorts. These included eight Japanese participants in cohort 7A.

[0616] Part B: 16 to 30 healthy adult participants

[0617] Approximately 16 healthy adult participants will be divided into 2 dosing cohorts. An additional 14 healthy adult participants may be enrolled in two additional optional cohorts.

[0618] Inclusion criteria:

[0619] Participants who met the following criteria were considered eligible for participation in clinical research:

[0620] 1. Participants voluntarily agreed to participate in this study and signed an Institutional Review Board (IRB)-approved informed consent form before any screening visit procedures.

[0621] 2. Males and females aged between 18 and 55 years (inclusive) at the screening visit.

[0622] 3. Female participants were considered eligible if they met reproductive inclusion criteria.

[0623] 4. Non-smoker (or user of other nicotine / tobacco (including e-cigarettes)) based on medical history (no nicotine use in the past year) and negative urine cotinine test at the screening visit and / or inclusion (Day -2).

[0624] 5. Body mass index (BMI) between 18.5 kg / m2 and 30.0 kg / m2 (inclusive) at the screening visit.

[0625] 6. Determined to be healthy by the principal investigator (PI) as determined by pre-study medical evaluation (medical history, physical examination, vital signs, 12-lead electrocardiogram [ECG], and clinical laboratory evaluations).

[0626] 7. At the Screening Visit and Enrollment (Day -2), vital signs (systolic and diastolic blood pressure and pulse rate) were assessed. If vital signs were out of range (at the Screening Visit and Enrollment [Day -2]), the Investigator could obtain two additional sets of vital signs. If vital signs were out of range at each of these 3 consecutive assessments and the Investigator judged them to be clinically relevant, the participant was ineligible for the study.

[0627] 8. The following applies to Japanese participants in optional Cohort 7A: To qualify as a Japanese participant, the participant must meet the following criteria:

[0628] First generation Japanese:

[0629] Born in Japan

[0630] · Parents and grandparents are of Japanese descent and were born in Japan

[0631] · No major changes in lifestyle since leaving Japan

[0632] · Lived outside of Japan for less than 10 years

[0633] Exclusion criteria

[0634] Participants who meet one or more of the following criteria are considered ineligible for clinical research:

[0635] 1. Participants have a history or evidence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immune, or psychiatric disorder as determined by the PI or designee.

[0636] 2. Participants have received monoclonal antibody therapy within 120 days prior to inclusion (Day -2).

[0637] 3. The participant suffers from any concurrent disease or condition that, in the opinion of the PI, makes the participant unsuitable for participation in the clinical research.

[0638] 4. Participants have a history of alcohol and / or illegal drug addiction within 2 years prior to inclusion.

[0639] 5. The participant tests positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or human immunodeficiency virus (HIV) antibody.

[0640] 6. Participant tested positive for urine ethanol at the Screening Visit or Enrollment (Day -2).

[0641] 7. Participants had urine drug levels (e.g., cocaine, amphetamines, barbiturates, opioids, benzodiazepines) at the screening visit or inclusion (Day -2). Tests were positive for narcotics and cannabinoids) and cotinine.

[0642] 8. Female participants who were breastfeeding or had a positive serum pregnancy test at the Screening Visit or Enrollment (Day -2).

[0643] 9. Participants have donated blood (>500mL) or blood products within 2 months (56 days) before inclusion (day -2).

[0644] 10. Participant has received study drug administration within 30 days or 5 half-lives (whichever is longer) prior to inclusion (Day -2).

[0645] 11. Participants have a history of allergy to study drugs, other therapeutic monoclonal antibodies, or any excipients, or to drugs with similar chemical structures.

[0646] 12. The participant is unable to understand the protocol requirements, instructions and study-related limitations, and the nature, scope and possible consequences of the clinical study.

[0647] 13. Participants are unlikely to comply with protocol requirements, instructions, and study-related restrictions, such as uncooperative attitude, inability to return for follow-up, and impossibility of completing the clinical study.

[0648] 14. Participants have been previously enrolled in this clinical study.

[0649] 15. Vulnerable participants, defined as individuals who are willing to voluntarily participate in clinical research, may be unduly influenced by expectations of benefits associated with participation (whether justified or not) or by retaliatory responses from higher-level members of their superiors if they refuse to participate (e.g., detainees, minors, and those unable to give informed consent).

[0650] 16. The participant tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription polymerase chain reaction (RT-PCR) before inclusion (day -2).

[0651] 17. Participants have clinical signs and symptoms consistent with SARS-CoV-2 infection, such as fever, dry cough, dyspnea, sore throat, fatigue, or laboratory-confirmed acute SARS-CoV-2 infection.

[0652] 18. Participants have a severe course of COVID-19 (COVID-19; extracorporeal membrane oxygenation, mechanical ventilation, intensive care unit hospitalization).

[0653] 19. The participant has had recent exposure (within 14 days prior to enrollment in the clinical unit [Day -2]) to someone with COVID-19 symptoms or who has tested positive for SARS-CoV-2.

[0654] 20. The participant had recently (within 14 days prior to enrollment in the clinical ward [Day -2]) visited a healthcare facility treating patients with COVID-19.

[0655] 21. Participants had received their final dose of the COVID-19 vaccine within 14 days prior to enrollment in the clinical ward (i.e., they must have completed vaccination at least 14 days prior to enrollment).

[0656] Exclusion criteria for CSF participants:

[0657] Participants who met one or more of the following criteria were deemed ineligible for CSF evaluation:

[0658] 22. Hypersensitivity to the anesthetics or derivatives used during CSF collection or to any medications used in the area where the lumbar puncture was performed.

[0659] 23. CSF collection was performed within 30 days before admission (day -2) to the clinical ward.

[0660] 24. Have a history of spinal deformity, major back surgery, clinically significant back pain, clinically significant abnormal X-rays, and / or injuries that, in the opinion of the investigator, would preclude the participant's participation in the study or CSF collection during the study.

[0661] 25. Persistent skin infection at the lumbar puncture injection site.

[0662] 26. Clinically significant coagulation test values ​​outside the normal reference range (prothrombin time / international normalized ratio, partial thromboplastin time) during screening.

[0663] Evaluation criteria:

[0664] Primary endpoint:

[0665] Safety and tolerability of the anti-TREM2 antibody “Ab-1” as assessed by adverse events (AEs), clinical laboratory tests, and vital sign measurements.

[0666] Secondary endpoints:

[0667] Single-dose and multiple-dose anti-TREM2 antibody "Ab-1" serum pharmacokinetic parameters: for example, the area under the serum or CSF concentration-time curve from predose (time 0) to the time of last quantifiable concentration (tlast) (AUC0-last), the area under the serum or CSF concentration-time curve from predose (time 0) extrapolated to infinite time (AUClast+Clast / λz) (AUC0-inf), maximum serum / cerebrospinal fluid concentration (Cmax), time to maximum serum / cerebrospinal fluid concentration (Tmax), terminal elimination half-life (t1 / 2), systemic clearance, volume of distribution at steady state, mean residence time, area under the serum or CSF concentration-time curve during the dosing interval, concentration prior to dose administration, accumulation rate (Cmax for the last dose divided by Cmax on day 1, and AUC0-tau [last dose] divided by AUC0-tau [first dose])

[0668] Single-dose anti-TREM2 antibody "Ab-1" CSF pharmacokinetic parameters: e.g., Cmax, Tmax, AUC0-inf, AUC0-last, λz, t1 / 2, and anti-TREM2 antibody "Ab-1" CSF concentrations on or after day 1 and day 58 / 59 after multiple-dose administration

[0669] Characterization of anti-drug antibody levels after single and multiple dose administration of anti-TREM2 antibody “Ab-1”

[0670] Exploratory endpoints:

[0671] Changes from baseline in exploratory pharmacodynamic biomarkers in CSF and serum (e.g., soluble triggering receptor expressed on myeloid cells 2 [sTREM2] biomarker, 10 kDa interferon-γ-induced protein [IP-10], monocyte chemoattractant protein-1 [MCP-1], colony stimulating factor-1 receptor [sCSF1R], and neurofilament light chain [NfL])

[0672] Number and proportion of Japanese participants reporting AEs / serious adverse events (SAEs) in the dosing cohorts that received a single dose

[0673] Single-dose serum pharmacokinetic parameters of anti-TREM2 antibody “Ab-1” in Japanese participants

[0674] Statistical methods:

[0675] Sample size considerations

[0676] This sample size was chosen based on clinical judgment and not on statistical power calculations. No formal sample size calculation was performed. The number of participants was chosen based on feasibility and was deemed adequate to meet the study objectives.

[0677] Data presentation / descriptive statistics

[0678] All demographic, safety, and pharmacokinetic / pharmacodynamic data are presented and summarized in tables using descriptive statistics by cohort, race, and visit / time, as appropriate. Pharmacokinetic data (serum and CSF) are also presented graphically, as appropriate. The number and percentage of AEs are presented by system organ class and preferred term list, broken down by cohort and race.

[0679] Mid-term results:

[0680] Overview

[0681] To date, the trial has included 82 healthy volunteers who received anti-TREM2 antibody "Ab-1" (n=68) or placebo (n=14) at doses of 1 mg / kg, 3 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg or 40 mg / kg. It was found that anti-TREM2 antibody "Ab-1" was safe and well tolerated in both the SAD and MAD cohorts administered.

[0682] All adverse events (AEs) were mild in severity, except for one moderate AE, and all AEs resolved without intervention. To date, no serious adverse events have been reported.

[0683] The anti-TREM2 antibody “Ab-1” exhibited dose-proportional pharmacokinetics with good half-life and brain penetration.

[0684] The anti-TREM2 antibody "Ab-1" achieved a dose-dependent, durable decrease in sTREM2 levels in the cerebrospinal fluid (CSF), demonstrating evidence of target engagement. Repeated dosing at 20 mg / kg was associated with a substantial decrease in sTREM2 levels, and decreases were still observed 28 days after the third and final dose. The anti-TREM2 antibody "Ab-1" is the first antibody reported to demonstrate persistence of TREM2 binding in a clinical setting.

[0685] The anti-TREM2 antibody “Ab-1” showed a persistent increase in sCSF1R levels in CSF after repeated dosing.

[0686] Dose escalation in the Phase 1 trial in healthy volunteers continues, and approval has been given to initiate a 60 mg / kg cohort in Australia.

[0687] In each double-blind cohort, 8 subjects were randomly assigned to receive a single intravenous administration of 1 mg / kg, 3 mg / kg, 10 mg / kg, 20 mg / kg, 30 mg / kg or 40 mg / kg of anti-TREM2 antibody "Ab-1" or placebo in the SAD part, and 20 mg / kg of anti-TREM2 antibody "Ab-1" or placebo once every 28 days in the MAD cohort, for a total of three administrations. In addition, for the collection of CSF, the open-label part of the trial is in progress. There are currently preliminary safety and tolerability data for one CSF SAD cohort (receiving a single intravenous dose of 3 mg / kg, 10 mg / kg or 20 mg / kg of VGL101) and one CSF MAD cohort (receiving 20 mg / kg of VGL101 once every 28 days, for a total of three drug administrations).

[0688] Safety and Tolerability

[0689] Across cohorts, all AEs were mild except for one moderate AE, and all resolved without intervention. No serious AEs (SAEs) or clinically significant abnormalities in vital signs, ECGs, or laboratory parameters were reported.

[0690] Single ascending dose pharmacokinetics (PK)

[0691] Figure 1 Serum pharmacokinetic data for the SAD cohort are shown. Doses up to 30 mg / kg over 28 days and 1 mg / kg, 3 mg / kg, 10 mg / kg, and 20 mg / kg over 84 days have been evaluated. All available doses up to 30 mg / kg demonstrated linear and dose-proportional pharmacokinetics with low variability.

[0692] Multiple ascending dose pharmacokinetics (PK)

[0693] Figure 2 Serum pharmacokinetic data from the first MAD cohort are shown, in which 20 mg / kg of anti-TREM2 antibody "Ab-1" was administered once every 28 days for a total of three infusions. The data showed that the half-life was approximately 27 days and steady-state was achieved between the 3rd and 4th doses, which supports the monthly dosing regimen.

[0694] The brain penetration of anti-TREM2 antibody "Ab-1" was between 0.1% and 0.2%.

[0695] Pharmacodynamics

[0696] Based on preclinical studies, reduced levels of soluble TREM2 (sTREM2), a proximity biomarker of TREM2 receptor binding, were predicted. Figure 3A The effect of anti-TREM2 antibody "Ab-1" on CSF sTREM2 in 18 healthy volunteers (administered with a single intravenous dose of 3 mg / kg, 10 mg / kg, and 20 mg / kg of anti-TREM2 antibody "Ab-1") is shown. sTREM2 showed a dose-dependent reduction relative to baseline, and the reduction in sTREM2 was statistically significant 2 weeks after a single dose of 10 mg / kg and 20 mg / kg of anti-TREM2 antibody "Ab-1".

[0697] Figure 3BThe effect of the anti-TREM2 antibody "Ab-1" on sTREM2 after three intravenous doses of 20 mg / kg (given once every 28 days) is shown. CSF levels of sTREM2 were evaluated at baseline (pre-dose), 48 hours and 28 days after the third and final doses. These data show that after repeated dosing of 20 mg / kg of the anti-TREM2 antibody "Ab-1", the reduction in sTREM2 relative to the pre-dose baseline was statistically significant, and it is noteworthy that the reduction was larger and the change was smaller compared to the single dose at the 48-hour time point. Similarly, the sTREM2 reduction was maintained for 28 days after the third and final doses, and the change was smaller compared to the single dose. These data can be used as the persistence of target binding of the anti-TREM2 antibody "Ab-1" in humans after repeated dosing for 28 days.

[0698] Soluble CSF1R (sCSF1R) is another biomarker of target engagement downstream of sTREM2 and microglial activation. Based on preclinical data, increased levels of sCSF1R in CSF are expected. Figure 4A-4B Increased sCSF1R and target binding by anti-TREM2 antibody "Ab-1" after single and repeated dosing, as observed for sTREM2, are shown, respectively. Reduced changes were again observed after repeated dosing.

[0699] ***

[0700] Although we have described several embodiments of the present invention, it is apparent that our basic examples can be modified to provide other embodiments utilizing the compounds and methods of the present invention. Therefore, it should be understood that the scope of the present invention is defined by the application and claims, rather than by the specific embodiments shown by way of example.

Claims

1. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) in a human patient, the method comprising administering to a patient in need thereof an anti-TREM2 antibody at a dose of about 1 mg / kg–100 mg / kg, wherein the anti-TREM2 antibody comprises: (a) a light chain variable region comprising CDRL1 having an amino acid sequence according to SEQ ID NO:2; CDRL2 having an amino acid sequence according to SEQ ID NO:3; and CDRL3 having an amino acid sequence according to SEQ ID NO:4, and a heavy chain variable region comprising CDRH1 having an amino acid sequence according to SEQ ID NO:6; CDRH2 having an amino acid sequence according to SEQ ID NO:7; and CDRH3 having an amino acid sequence according to SEQ ID NO:8; or (b) a light chain variable region having an amino acid sequence according to SEQ ID NO: 1 and a heavy chain variable region having an amino acid sequence according to SEQ ID NO:

5.

2. The method of claim 1, wherein the anti-TREM2 antibody: (i) is IgG, optionally IgG 1 ; (ii) is IgG1, the IgG 1 comprising a variant constant region having one or more mutations selected from the group consisting of: R292C, N297G, V302C, D356E or L358M, according to EU numbering; and / or (iii) contains a kappa light chain constant region.

3. The method of claim 1, wherein the anti-TREM2 antibody is the anti-TREM2 antibody VGL101, and the anti-TREM2 antibody VGL101 comprises a light chain having an amino acid sequence of SEQ ID NO:9, and a heavy chain having an amino acid sequence of SEQ ID NO:

10.

4. The method of claim 1, wherein the method comprises administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody.

5. The method of claim 1, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody.

6. The method of claim 1, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a week by intravenous infusion, optionally wherein the intravenous infusion is about 60 minutes.

7. A liquid preparation comprising an anti-TREM2 antibody VGL101 at a concentration of approximately 140 mg / mL, and a pharmaceutically acceptable excipient and / or carrier.

8. The liquid formulation of claim 7, further comprising one or more of the following: (a) sodium acetate at a concentration of about 15 mM; (b) sucrose at a concentration of about 9% (w / v) by volume of the total liquid formulation; (c) polysorbate 80 at a concentration of about 0.01% (w / v) of the total liquid formulation volume; and / or (d) a pH of about 5.

2.

9. A liquid formulation at about pH 5.2, comprising: the anti-TREM2 antibody VGL101 at a concentration of about 140 mg / mL; Sodium acetate at a concentration of about 15 mM; Sucrose at a concentration of about 9% (w / v) by volume of the total liquid formulation; and Polysorbate 80 at a concentration of about 0.01% (w / v) of the total liquid formulation volume.

10. A method for treating adult-onset leukoencephalopathy with axonal spheroids and pigmented glial cells (ALSP) in a human patient, the method comprising administering to the patient in need thereof a therapeutically effective amount of the liquid formulation of claim 9.

11. The method of claim 10, wherein the method comprises administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody VGL101, optionally a dose of about 20 mg / kg–40 mg / kg of the anti-TREM2 antibody.

12. The method of claim 10, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody VGL101.

13. The method of claim 10, wherein the method comprises administering the anti-TREM2 antibody VGL101 to the human patient once a week by intravenous infusion, optionally wherein the intravenous infusion is about 60 minutes.

14. A method for reducing the level of sTREM2 or sCSF1R in a subject, the method comprising administering anti-TREM2 antibody VGL101 to the subject at a dose of about 1 mg / kg–100 mg / kg.

15. The method of claim 14, wherein the level of sTREM2 or sCSF1R is assessed prior to administration of VGL101.

16. The method of claim 14, wherein the level of sTREM2 or sCSF1R is the level in cerebrospinal fluid (CSF).

17. The method of any one of claims 14, wherein the level of sTREM2 or sCSF1R is reduced by about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, or about 100%.

18. The method of claim 14, wherein the method comprises administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody VGL101, optionally a dose of about 20 mg / kg–40 mg / kg of the anti-TREM2 antibody.

19. The method of claim 14, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody VGL101.

20. The method of claim 14, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a week by intravenous infusion, optionally wherein the intravenous infusion is about 60 minutes.

21. A method for binding or stimulating TREM2 in a subject, the method comprising administering to the subject the anti-TREM2 antibody VGL101 at a dose of about 1 mg / kg–100 mg / kg.

22. The method of claim 21, wherein the method comprises administering to the human patient a dose of about 1 mg / kg–60 mg / kg of the anti-TREM2 antibody, optionally a dose of about 20 mg / kg–40 mg / kg of the anti-TREM2 antibody.

23. The method of claim 21, wherein the method comprises administering to the human patient a dose of about 1 mg / kg, about 3 mg / kg, about 10 mg / kg, about 20 mg / kg, or about 40 mg / kg of the anti-TREM2 antibody.

24. The method of claim 21, wherein the method comprises administering the anti-TREM2 antibody to the human patient once a week by intravenous infusion, optionally wherein the intravenous infusion is about 60 minutes.